

Curriculum Vitae

Kenneth D. Aldape MD

A. Date Curriculum Vitae is Prepared: 2015 March 2

B. Biographical Information

Primary Office Toronto Medical Discovery Tower (TMDT)
East Tower 14-704
101 College St
Toronto, Ontario, Canada
M5G1L7
Telephone 416-634-8728
Email ken.aldape@uhn.ca

1. EDUCATION

Degrees

1986 - 1991 MD, Medicine, Dept of Medicine, University of California, San Francisco, California, United States
1979 - 1986 BAS, Philosophy and Biology, Stanford University, Palo Alto, California, United States

Postgraduate, Research and Specialty Training

1993 - 1995 Clinical Fellowship, Neuropathology, University of California, San Francisco, California, United States
1993 - 1995 Research Fellowship, Neuro-Oncology, Preuss Laboratory for Molecular Neuro-Oncology, San Francisco, California, United States
1992 - 1993 Chief Resident, Anatomic Pathology, University of California, San Francisco, California, United States
1991 - 1992 Clinical Residency, Anatomic Pathology, University of California, San Francisco, California, United States
1989 - 1990 Post-Sophomore Fellowship, Anatomic Pathology, University of California, San Francisco, California, United States

Qualifications, Certifications and Licenses

2001 - present Medical License, Texas Medical Board, Texas, United States, License / Membership #: L2088
1992 - present Medical License, The Medical Board of California, California, United States, License / Membership #: G75302
1999 Sep Diplomat, American Board of Pathology
1999 Sep Board Certified in Neuropathology, American Board of Pathology
1999 Sep Board Certified in Anatomic Pathology, American Board of Pathology

2. EMPLOYMENT

Current Appointments

- 2014 Aug - present Senior Scientist, Director, MacFeeters-Hamilton Brain Tumor Centre, Pathology, Toronto General Hospital, University of Toronto, Ontario Cancer Institute, Toronto, Ontario, Canada
- 2014 Aug - present Professor, Department of Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Laboratory Medicine and Pathobiology, Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada

Previous Appointments

CLINICAL

- 2012 Nov - 2014 Feb Department Chair, Division of Pathology/Lab Medicine, Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
- 2011 Jan - 2014 Feb Medical Director, Molecular Diagnostics (Solid Tumors), Division of Pathology/Lab Medicine, Department of Pathology/Laboratory Medicine, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States

CONSULTING

- 2008 - 2010 Member, Scientific Advisory Board, Castle Biosciences, Houston, Texas, United States
Consultant for development of multigene outcome predictor in glioblastoma

HOSPITAL

- 1995 - 2001 Consultant Neuropathologist, Neuropathology Service, Moffitt Hospital, San Francisco, California, United States
- 1995 - 2001 Attending Physician, Autopsy Service, Moffitt Hospital, San Francisco, California, United States

RESEARCH

- 2011 Jan - 2014 Feb Kenneth D. Muller Professorship in Tumor Genetics, Division of Pathology/Lab Medicine, Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States

UNIVERSITY - RANK

- 2009 Jan - 2014 Feb Adjunct Professor, Epidemiology and Disease Prevention, School of Public Health, University of Texas, Houston, Texas, United States
- 2007 Jan - 2014 Feb Professor, Division of Pathology/Lab Medicine, Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
- 2001 - 2007 Associate Professor, Division of Pathology/Lab Medicine, Department of Pathology, MD Anderson Cancer Center, University of Texas, Houston, Texas, United States
- 1995 - 2001 Assistant Professor, Department of Pathology, School of Medicine, University of California, San Francisco, San Francisco, California, United States

3. HONOURS AND CAREER AWARDS

Distinctions and Research Awards

NATIONAL

Received

- 2014 **Guha Award for Excellence in Neuro-Oncology Research**, Society for Neuro-Oncology. (Distinction)
- 2011 **Levin Award for Contributions to Neuro-Oncology Research**, Society for Neuro-Oncology. (Distinction)

Kenneth D. ALDAPE

2011 **Translational Research Award**, Society for Neuro-Oncology Annual Meeting. (Distinction)
2005 - 2011 **Best Doctors in America**, Best Doctors. (Distinction)
1990 **Award for Academic Excellence and Achievement**, American Society of Clinical Pathologists. (Distinction)

LOCAL

Received

1990 **Dean's Prize for Medical Student Research**, University of California, San Francisco. (Distinction)

Teaching and Education Awards

LOCAL

Received

1992 **Academic Pathology Intradepartmental Award for Medical Student Teaching**, University of California, San Francisco
1990 **Academic Pathology Intradepartmental Award for Medical Student Teaching**, University of California, San Francisco

4. PROFESSIONAL AFFILIATIONS AND ACTIVITIES

Professional Associations

2010 - present **Member**, Association for Molecular Pathology
2009 - present **Member**, American Society for Clinical Oncology
1999 - present **Member**, Society for Neuro-Oncology
1992 - present **Member**, American Association for Cancer Research
1992 - present **Member**, American Association of Neuropathologists
2011 - 2013 **President**, Society for Neuro-Oncology

Administrative Activities

NATIONAL

Accelerate Brain Cancer Cure

2013 Jan **Session Chair**, Lower Grade Glioma, San Francisco, California.

American Association of Cancer Research, Annual Meeting

2004 Apr **Session Chair**, Molecular Markers, Los Angeles, California.

American Association of Neuropathologists

2006 Oct **Session Chair**, Glial Tumors, San Francisco, California.
2003 Jun **Session Chair**, Glial Tumors, Denver, Colorado.
2000 Jun **Session Chair**, Glial Tumors, Portland, Oregon.

National Cancer Institute

Kenneth D. ALDAPE

2007 - 2009 **Member**, Steering Committee, The Cancer Genome Atlas (TCGA) project

National Comprehensive Cancer Network

2011 - 2014 **Member**, Task Force to Evaluate the Clinical Utility of Tumor Markers in Oncology

Pathology of the 21st Century Conference

2011 May **Co-Organizer**, Houston, Texas.

Radiation Therapy Oncology Group

2004 - 2014 **Member**, Brain Tumor Committee

Society for Neuro-Oncology

2009 - 2010 **Chair**, Scientific Program, 2010 Annual Meeting

2008 - 2014 **Chair**, Awards Committee

2007 - 2014 **Member**, SNO Board of Directors

Society for Neuro-Oncology Annual Meeting

2010 Nov **Session Program Chair**, Molecular Markers, Montreal, Canada.

2008 Nov **Session Chair**, Molecular Markers, Las Vegas, Nevada.

2007 Nov **Session Chair**, Molecular Markers, Dallas, Texas.

2003 Nov **Session Chair**, Molecular Markers, Keystone, Colorado.

LOCAL

Institute for Personalized Cancer Therapy

2008 - 2014 **Member**, Steering/Liaison Committee

The University of Texas MD Anderson Cancer Center

2011 - present **Member**, Executive Committee, Department of Pathology, Division of Pathology/Lab Medicine, Houston, Texas, United States.

2006 - present **Member**, Brain Tumor Center Executive Committee, Houston, Texas, United States.

2003 - present **Member**, Clinical Research Subcommittee, Brain Tumor Center, Houston, Texas, United States.

2002 - present **Director**, Central Nervous System Tissue Bank, Houston, Texas, United States.

2011 - 2014 **Member**, Internal Advisory Board, Center for Advanced Biomedical Imaging Research (CABIR), Houston, Texas, United States.

2011 - 2014 **Member**, Physician-Scientist Program Advisory Committee

2011 - 2014 **Member**, Molecular Testing Evaluation Committee

2010 - 2014 **Member**, CPRIT-TRIUMPH Program

2010 - 2014 **Member**, Translational Research Faculty Development Committee

2010 - 2011 **Member**, Search Committee - NeuroOncology Basic Research Position

2010 - 2011 **Member**, Search Committee - Vice President for Clinical Research

2009 - 2014 **Member**, Research Laboratory Space Sub Committee

2004 Jan - 2014 **Member**, Human Genetics Program, Graduate School of Biomedical Sciences, Houston, Texas, United States.

UCSF Cancer Center

Kenneth D. ALDAPE

1998 - 2001 **Member**, Neuro-Oncology Program, San Francisco, California, United States.

University of California, San Francisco

1999 - 2001 **Member**, Cancer Genetics Program, San Francisco, California, United States.

1998 - 2001 **Member**, Biomedical Sciences Graduate Program, San Francisco, California, United States.

1995 - 2001 **Member**, Brain Tumor Research Center, San Francisco, California, United States.

Peer Review Activities

EDITORIAL BOARDS

Editor

2011 - present "Breaking Advances" section, Cancer Research

Member

2009 - present Editorial Review Board, Journal of Pathology

2008 - present Editorial Review Board, Brain Pathology

2006 - present Editorial Review Board, Clinical Cancer Research

2006 - present Editorial Review Board, Neuro-Oncology

1999 - 2002 Editorial Review Board, Journal of Neuropathology and Experimental Neurology

Executive Editor

2013 - present Neuro-Oncology

International Editor

2012 - present Brain Tumor Pathology

GRANT REVIEWS

External Grant Reviewer

2009 Department of Defense, PRMRP09 - Molecular Signatures of Tumors, Chair

2009 NIH, Special Emphasis Panel on Mouse Models of Human Cancer, Member

2008 - 2009 MD Anderson Cancer Center, Institutional Research Grant Study Section, Chair

2007 - 2008 MD Anderson Cancer Center, Institutional Research Grant Study Section, Vice Chair

2006 - 2007 MD Anderson Cancer Center, Institutional Research Grant Study Section, Member

2005 - 2006 MD Anderson Cancer Center, Institutional Research Grant Study Section, Chair

2004 - 2005 MD Anderson Cancer Center, Institutional Research Grant Study Section, Vice Chair

MANUSCRIPT REVIEWS

Reviewer

2010 - present Cancer Cell

2010 - present Nature Medicine

2006 - present Molecular Cancer Therapeutics

2006 - present Neurology

2005 - present American Journal of Pathology

2005 - present PNAS

2004 - present Journal of Clinical Oncology

2003 - present Oncogene

2002 - present Cancer

2001 - present Cancer Research

EXTERNAL ADVISORY BOARD

Member

2013 - present MD Anderson Cancer Center SPORE in Brain Cancer
2006 - present Mayo Clinic SPORE in Brain Cancer
2006 - present UCSF Brain Tumor Research Center

SCIENTIFIC ADVISORY BOARD

Member

2010 - present American Brain Tumor Association
2006 - present Sontag Foundation for Brain Tumor Research

C. Research Funding

1. GRANTS, CONTRACTS AND CLINICAL TRIALS

PEER-REVIEWED GRANTS

FUNDED

2008 - present **Reference Pathologist and Integral Markers.** Phase III trial of concurrent and adjuvant temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma. Radiation Therapy Oncology Group. RTOG 0834. PI: Gilbert, Mark R. [Protocols]

2010 Dec - 2011 Dec **Co-Investigator.** Histopathology Review for CENTRIC clinical trial. Merck & Co. Inc. LS2011-0034133JW01. 152,000. [Grants]
1%, (\$76,000/year).

2010 Jul - 2012 Dec **Principal Investigator.** Personalized Cancer Therapy for Glioma. Longwell Family Foundation. 200,000. [Grants]
0.9 months, 7/1/2010–12/31/2012, (\$100,000/year).

2010 Jul - 2012 Jun **Principal Investigator.** Central pathology review and integral marker analysis for RTOG 0837 and 0834. American College of Radiology. 100,000. [Grants]
1%, 7/1/2010–6/30/2012, (\$50,000/year).

2010 Jul - 2011 Jun **Co-Investigator.** Clinical Application of Markers to Assess Pathways Activated in Cancer. Perot Foundation. PI: Hamilton, S. 80,000. [Grants]
7/1/2010–6/30/2011.

2010 Jul - 2011 Jun **Co-Investigator.** Ivy Glioblastoma Atlas. Ben & Catherine Ivy Foundation (The). 100,000. [Grants]
0.36 months, 7/1/2010–6/30/2011.

2010 Mar - 2014 Dec **Co-Investigator.** International Case Control Study of Malignant Gliomas. National Institutes of Health (NIH) (USA). NCI. R01-CA139020. PI: Bondy, Melissa. 100,000. [Grants]
1.2 months, 3/18/2010–12/31/2014, (\$25,000/year).

2010 Jan - 2010 Dec **Principal Investigator.** A combined molecular and clinical predictor of progression vs. pseudoprogression in newly diagnosed GBM. Brain Tumor Funder's Collaborative. 100,000.

[Grants]
0.45 months, 1/1/2010–12/31/2010.

- 2009 Sep - 2014 Jul **Investigator.** Integrative Pipeline for Analysis & Translational Application of TCGA Data (GDAC). National Institutes of Health (NIH) (USA). NCI. 1 U24 CA143883-01. PI: Weinstein, John N. 50,000. [Grants]
0.6 months, 9/29/2009–7/31/2014, (\$10,000/year).
- 2009 Sep - 2012 Aug **Co-Investigator.** Towards a Molecular Recursive Partitioning Analysis. National Institutes of Health (NIH) (USA). NCI. 1 RC2 CA148190 01. PI: Chakravarti, Arnab. 649,370. [Grants]
1.2 months, 9/30/2009–8/31/2012, (\$324,675/year).
- 2009 Aug - 2012 Jul **Principal Investigator.** Development of a biomarker panel to predict response to cediranib in newly diagnosed Glioblastoma. AstraZeneca Canada Inc. Research Collaboration Alliance. LS2006-00016301. [Grants]
0.12 months, 8/1/2009–7/31/2012, (\$125,000/year).
- 2009 Jul - 2011 Jun **Principal Investigator.** Role of YKL-40-Beta-Catenin signaling axis in GBM progression and radio-resistance. National Brain Tumor Foundation. 200,000. [Grants]
0.45 months, 7/1/2009–6/30/2011, (\$100,000/year).
- 2009 May - 2012 May **Principal Investigator.** Central Pathology Review and Integral Marker Analysis. American College of Radiology. RTOG0825. 430,000. [Grants]
0.9 months, Pending extension, 5/22/2009–5/31/2012, (\$215,000/year).
- 2009 Jan - 2012 Dec **Co-Principal Investigator.** Glioma Cancer Stem Cells and Tumor-Derived Mesenchymal Stem Cells: Role and Cross-Talk in Human Gliomas. The Ben and Catherine IVY Foundation. 11-02-15533. PI: **Aldape**, Lang. 750,000. [Grants]
0.12 months, 1/1/2009–12/31/2012, (\$250,000/year).
- 2009 Jan - 2011 Jun **Reference Pathologist.** Histopathology Examination. Merck KGAA. EMD 121 974-011. 250,000. [Grants]
0.12 months, 1/1/2009–6/30/2011, (\$125,000/year).
- 2009 Jan - 2010 Dec **Principal Investigator.** Individualization /optimization of treatment in GBM. The Dr. Marnie Rose Foundation. 80,000. [Grants]
10%, 1/1/2009–12/31/2010.
- 2008 Sep - 2013 Aug **Core Leader.** Pathology Core (Core B), SPORE in Brain Cancer. National Institutes of Health (NIH) (USA). P50 CA127001. PI: WKA Yung. 636,300. [Grants]
1.2 months, 9/1/2008–8/31/2013, (\$127,260/year).
- 2008 Sep - 2013 Aug **Project Leader.** Predictors of outcome in glioblastoma-Project 3 SPORE in Brain Cancer. National Institutes of Health (NIH) (USA). P50 CA127001. PI: WKA Yung. 806,835. [Grants]
1.2 months, 9/1/2008–8/31/2013, (\$161,367/year).
- 2008 Jul - 2013 Jun **Co-Principal Investigator.** SPORE in Brain Cancer. National Institutes of Health (NIH) (USA). NCI. PI: Yung, WKA. 806,835. [Grants]
1.2 months, 7/1/2008–6/30/2013, (\$161,367/year).
- 2008 Jun - 2010 May **Principal Investigator.** Role of YKL-40-beta-catenin signaling axis in GBM progression and radio-resistance. Brain Tumor Society (The) (TBTS). 200,000. [Grants]
10%, 6/1/2008–5/31/2010, (\$100,000/year).

Kenneth D. ALDAPE

- 2008 Jun - 2009 May **Principal Investigator.** MicroRNAs in oligodendroglioma. National Brain Tumor Foundation. 50,000. [Grants]
10%, 6/1/2008–5/31/2009.
- 2008 - 2012 **Reference Pathologist and Integral Markers.** A phase III double blind placebo-controlled trial of conventional chemoradiation and adjuvant temozolomide plus bevacizumab vs. conventional concurrent chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. Radiation Therapy Oncology Group. RTOG 0825. PI: Gilbert, Mark R. [Protocols]
- 2008 - 2012 **Reference Pathologist and Integral Markers.** Phase II, randomized double-blind, placebo-controlled trial of conventional chemoradiation and adjuvant temozolomide plus cediranib vs. conventional chemoradiation and adjuvant temozolomide in patients with newly diagnosed glioblastoma. Radiation Therapy Oncology Group. RTOG 0837. PI: Batchelor, Tracy. [Protocols]
- 2008 - 2009 **Reference Pathologist.** Phase II trial in recurrent glioblastoma, bevacizumab registration trial. Genentech Inc. PI: Friedman, Henry. [Protocols]
- 2007 Sep - 2011 Aug **Principal Investigator.** Prediction of Response in Glioblastoma to Individualized treatment and target refractory tumors. The V Foundation for Cancer Research. RTOG 0525. 600,000. [Grants]
0.6 months, 9/1/2007–8/31/2011, (\$200,000/year).
- 2007 Jun - 2014 Jul **Project Leader.** Collaborative Ependymoma Research Network. Mathiel Foundation. CERN08-01. PI: M. Gilbert. 1,000,000. [Grants]
0.12 months, 6/1/2007–7/31/2014, (\$200,000/year).
- 2006 Dec - 2009 Nov **Principal Investigator.** SAIC-Frederick: To provide tumor tissue / neuropathology expertise to the Cancer Genome Atlas Network. National Institutes of Health (NIH) (USA). NCI. 200,000. [Grants]
10%, 12/1/2006–11/30/2009, (\$66,667/year).
- 2006 Sep - 2012 Aug **Project Leader.** Molecular genetic predictors of outcome in glioblastoma. Brain Tumor Funder's Collaborative. PI: Mehta, M. 200,000. [Grants]
0.72 months, 9/1/2006–8/30/2012, (\$40,000/year).
- 2006 Jul - 2011 Jun **Project Leader.** Role of YKL-40 in breast cancer metastases to the brain. Department of Defense (USA). W81XWH-062-0033. PI: Steeg, P. 500,000. [Grants]
0.45 months, 7/1/2006–6/30/2011, (\$100,000/year).
- 2006 Apr - 2011 Mar **Project Leader.** Gliogene. National Institutes of Health (NIH) (USA). NCI. PI: Bondy, M. 20,000. [Grants]
0.48 months, 4/1/2006–3/30/2011, (\$4,000/year).
- 2006 - 2011 **Reference Pathologist and Integral Markers.** Phase II trial of dasatinib in patients with recurrent glioblastoma. Radiation Therapy Oncology Group. RTOG 0627. PI: Lassman, Andrew B. [Protocols]
- 2006 - 2010 **Reference Pathologist.** Phase II study of bevacizumab with irinotecan in recurrent glioblastoma. Radiation Therapy Oncology Group. RTOG 0625. PI: Gilbert, Mark R. [Protocols]
- 2005 - 2008 **Reference Pathologist.** Phase III Trial Comparing Conventional Adjuvant Temozolomide

With Dose-Intensive Temozolomide in Patients with Newly Diagnosed Glioblastoma. Radiation Therapy Oncology Group. RTOG 0525. PI: Gilbert, Mark R. [Protocols]

- 2004 Dec - 2009 Nov **Reference Pathologist.** North American Brain Tumor Consortium. National Institutes of Health (NIH) (USA). NCI. PI: Prados, M. 40,000. [Grants]
10%, 12/1/2004–11/30/2009, (\$8,000/year).
- 2004 **Reference Pathologist.** Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. North American Brain Tumor Consortium. NABTC 04-01. PI: Prados, Michael D. [Protocols]
- 2003 **Reference Pathologist.** Phase I study of temozolomide and irinotecan for recurrent malignant gliomas. North American Brain Tumor Consortium. NABTC 03-01. PI: Prados, Michael D. [Protocols]
- 2002 **Reference Pathologist.** Phase I-II study of imatinib mesylate for recurrent malignant gliomas. North American Brain Tumor Consortium. NABTC 02-09. PI: Prados, Michael D. [Protocols]
- 2002 **Reference Pathologist.** Phase I-II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma. North American Brain Tumor Consortium. NABTC 02-05. PI: Prados, Michael D. [Protocols]
- 2002 **Reference Pathologist.** Phase II trial of tipifarnib in patients with recurrent malignant glioma. North American Brain Tumor Consortium. NABTC 02-04. PI: Prados, Michael D. [Protocols]
- 2001 **Reference Pathologist.** Phase II study of imatinib mesylate for recurrent meningiomas. North American Brain Tumor Consortium. NABTC 01-08. PI: Prados, Michael D. [Protocols]
- 2001 **Reference Pathologist.** Phase II trial of gefitinib in patients with recurrent meningioma. North American Brain Tumor Consortium. NABTC 01-03. PI: Prados, Michael D. [Protocols]
- 2000 **Reference Pathologist.** Phase II trial of erlotinib in patients with recurrent meningioma. North American Brain Tumor Consortium. NABTC 00-01. PI: Prados, Michael D. [Protocols]

D. Publications

1. PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Penas-Prado M, Hess KR, Fisch MJ, Lagrone LW, Groves MD, Levin VA, De Groot JF, Puduvalli VK, Colman H, Volas-Redd G, Giglio P, Conrad CA, Salacz ME, Floyd JD, Loghini ME, Hsu SH, Gonzalez J, Chang EL, Woo SY, Mahajan A, **Aldape KD**, Yung WK, Gilbert MR; MD Anderson Community Clinical Oncology Program and the Brain Tumor Trials Collaborative. Randomized phase II adjuvant factorial study of dose-dense temozolomide alone and in combination with isotretinoin, celecoxib, and/or thalidomide for glioblastoma. *Neuro Oncol.* 2015 Feb;17(2):266-73. **Coauthor or Collaborator.**
2. Jalali A, Amirian ES, Bainbridge MN, Armstrong GN, Liu Y, Tsavachidis S, Jhangiani SN, Plon SE, Lau CC, Claus EB, Barnholtz-Sloan JS, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Davis FG, Lai R, Shete S, **Aldape K**, Amos CI, Muzny DM, Gibbs RA, Melin BS, Bondy ML. Targeted sequencing in chromosome 17q linkage region identifies familial glioma candidates in the gliogene consortium. *Sci Rep.* 2015 Feb;5(10):1-8. **Coauthor or Collaborator.**

3. Xue J, Chen Y, Wu Y, Wang Z, Zhou A, Zhang S, Lin K, **Aldape K**, Majumder S, Lu Z, Huang S. Tumour suppressor TRIM33 targets nuclear β -catenin degradation. *Nat Commun.* 2015 Feb;2(6). **Coauthor or Collaborator.**
4. Olar A, Wani KM, Alfaro-Munoz KD, Heathcock LE, van Thuijl HF, Gilbert MR, Armstrong TS, Sulman EP, Cahill DP, Vera-Bolanos E, Yuan Y, Reijneveld JC, Ylstra B, Wesseling P, **Aldape KD**. IDH mutation status and role of WHO grade and mitotic index in overall survival in grade II-III diffuse gliomas. *Acta Neuropathol.* 2015 Feb;e-pub. **Senior Responsible Author.**
5. Jabbar KJ, Luthra R, Patel KP, Singh RR, Goswami R, **Aldape KD**, Medeiros LJ, Routbort MJ. Comparison of Next-generation Sequencing Mutation Profiling With BRAF and IDH1 Mutation-specific Immunohistochemistry. *Am J Surg Pathol.* 2015 Jan;e-pub. **Coauthor or Collaborator.**
6. Chen K, Meric-Bernstam F, Zhao H, Zhang Q, Ezzeddine N, Tang LY, Qi Y, Mao Y, Chen T, Chong Z, Zhou W, Zheng X, Johnson A, **Aldape KD**, Routbort MJ, Luthra R, Kopetz S, Davies MA, de Groot J, Moulder S, Vinod R, Farhangfar CJ, Mills Shaw K, Mendelsohn J, Mills GB, Karina Eterovic A. Clinical Actionability Enhanced through Deep Targeted Sequencing of Solid Tumors. *Clin Chem.* 2015 Jan;e-pub. **Coauthor or Collaborator.**
7. Bainbridge MN, Armstrong GN, Gramatges MM, Bertuch AA, Jhangiani SN, Doddapaneni H, Lewis L, Tombrello J, Tsavachidis S, Liu Y, Jalali A, Plon SE, Lau CC, Parsons DW, Claus EB, Barnholtz-Sloan J, Il'yasova D, Schildkraut J, Ali-Osman F, Sadetzki S, Johansen C, Houlston RS, Jenkins RB, Lachance D, Olson SH, Bernstein JL, Merrell RT, Wrensch MR, Walsh KM, Davis FG, Lai R, Shete S, **Aldape K**, Amos CI, Thompson PA, Muzny DM, Gibbs RA, Melin BS, Bondy ML; Gliogene Consortium. Germline mutations in shelterin complex genes are associated with familial glioma. *J Natl Cancer Inst.* 2014 Dec;107(1). **Coauthor or Collaborator.**
8. Agnihotri S, **Aldape KD**, Zadeh G. Isocitrate dehydrogenase status and molecular subclasses of glioma and glioblastoma. *Neurosurg Focus.* 2014 Dec;6(37). **Coauthor or Collaborator.**
9. Cachia D, Wani K, Penas-Prado M, Olar A, McCutcheon IE, Benjamin RS, Armstrong TS, Gilbert MR, **Aldape KD**. C11orf95-RELA fusion present in a primary supratentorial ependymoma and recurrent sarcoma. *Brain Tumor Pathol.* 2014 Nov. **Coauthor or Collaborator.**
10. Singh RR, Patel KP, Routbort MJ, **Aldape K**, Lu X, Manekia J, Abraham R, Reddy NG, Barkoh BA, Veliyathu J, Medeiros LJ, Luthra R. Clinical massively parallel next-generation sequencing analysis of 409 cancer-related genes for mutations and copy number variations in solid tumours. *British Journal of Cancer.* 2014 Nov;10(111):2014-23. **Coauthor or Collaborator.**
11. Said R, Ye Y, Falchook GS, Janku F, Naing A, Zinner R, Blumenschein GR Jr, Fu S, Hong DS, Piha-Paul SA, Wheler JJ, Kurzrock R, Palmer GA, **Aldape K**, Hess KR, Tsimberidou AM. Outcomes of patients with advanced cancer and KRAS mutations in phase I clinical trials. *Oncotarget.* 2014 Oct;5(19):8937-46. **Coauthor or Collaborator.**
12. Chen JC, Alvarez MJ, Talos F, Dhruv H, Rieckhof GE, Iyer A, Diefes KL, **Aldape K**, Berens M, Shen MM, Califano A. Identification of causal genetic drivers of human disease through systems-level analysis of regulatory networks. *Cell.* 2014 Oct;159(2):402-414. **Coauthor or Collaborator.**
13. Mandel JJ, Olar A, **Aldape KD**, Tremont-Lukats IW. Lmbrolizumab induced central nervous system (CNS) toxicity. *J Neurol Sci.* 2014 Sep 15;344(1-2):229-31. **Coauthor or Collaborator.**
14. Louis DN, Perry A, Burger P, Ellison DW, Reifenberger G, von Deimling A, **Aldape K**, Brat D, Collins VP, Eberhart C, Figarella-Branger D, Fuller GN, Giangaspero F, Giannini C, Hawkins C, Kleihues P, Korshunov A, Kros JM, Lopes MB, Ng HK, Ohgaki H, Paulus W, Pietsch T, Rosenblum M, Rushing E, Soylemezoglu F, Wiestler O, Wesseling P. International Society of Neuropathology-Haarlem Consensus Guidelines, for Nervous System Tumor Classification and Grading. *Brain Pathol.* 2014 Sep;24(5):429-35. **Coauthor or Collaborator.**
15. Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E, Barrett L, Zhuang Y, Verma I, Benezra R, **Aldape K**, Iavarone A, Lasorella A. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. *J Clin Invest.* 2014 Sep;124(9):4134. **Coauthor or Collaborator.**

16. Stupp R, Hegi ME, Gorlia T, Erridge SC, Perry J, Hong YK, **Aldape KD**, Lhermitte B, Pietsch T, Grujcic D, Steinbach JP, Wick W, Tarnawski R, Nam DH, Hau P, Weyerbrock A, Taphoorn MJ, Shen CC, Rao N, Thurzo L, Herrlinger U, Gupta T, Kortmann RD, Adamska K, McBain C, Brandes AA, Tonn JC, Schnell O, Wiegel T, Kim CY, Nabors LB, Reardon DA, van den Bent MJ, Hicking C, Markivskyy A, Picard M, Weller M, for the European Organisation for Research and Treatment of Cancer (EORTC), the Canadian Brain Tumor Consortium, and the CENTRIC study team. Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial. *Lancet Oncol*. 2014 Aug;S1470-2045(14):70379-1. **Coauthor or Collaborator**.
17. Davis CF, Ricketts CJ, Wang M, Yang L, Cherniack AD, Shen H, Buhay C, Kang H, Kim SC, Fahey CC, Hacker KE, Bhanot G, Gordenin DA, Chu A, Gunaratne PH, Biehl M, Seth S, Kaiparettu BA, Bristow CA, Donehower LA, Wallen EM, Smith AB, Tickoo SK, Tamboli P, Reuter V, Schmidt LS, Hsieh JJ, Choueiri TK, Hakimi AA, The Cancer Genome Atlas Research Network, Chin L, Meyerson M, Kucherlapati R, Park WY, Robertson AG, Laird PW, Henske EP, Kwiatkowski DJ, Park PJ, Morgan M, Shuch B, Muzny D, Wheeler DA, Linehan WM, Gibbs RA, Rathmell WK, Creighton CJ, The Cancer Genome Atlas Research Network. The Somatic Genomic Landscape of Chromophobe Renal Cell Carcinoma. *Cancer Cell*. 2014 Aug;S1535-6108(14):00304-3. **Coauthor or Collaborator**.
18. Siroy AE, Boland GM, Milton DR, Roszik J, Frankian S, Malke J, Haydu L, Prieto VG, Tetzlaff M, Ivan D, Wang WL, Torres-Cabala C, Curry J, Roy-Chowdhuri S, Broaddus R, Rashid A, Stewart J, Gershenwald JE, Amaria RN, Patel SP, Papadopoulos NE, Bedikian A, Hwu WJ, Hwu P, Diab A, Woodman SE, **Aldape KD**, Luthra R, Patel KP, Shaw KR, Mills GB, Mendelsohn J, Meric-Bernstam F, Kim KB, Routbort MJ, Lazar AJ, Davies MA. Beyond BRAFV600: clinical mutation panel testing by next-generation sequencing in advanced melanoma. *J Invest Dermatol*. 2014 Aug. **Coauthor or Collaborator**.
19. Kusne Y, Carrera-Silva EA, Perry AS, Rushing EJ, Mandell EK, Dietrich JD, Errasti AE, Gibbs D, Berens ME, Loftus JC, Hulme C, Yang W, Lu Z, **Aldape K**, Sanai N, Rothlin CV, Ghosh S. Targeting aPKC disables oncogenic signaling by both the EGFR and the proinflammatory cytokine TNF α in glioblastoma. *Sci Signal*. 2014 Aug;7(338):ra75. **Coauthor or Collaborator**.
20. Vera-Bolanos E, **Aldape K**, Yuan Y, Wu J, Wani K, Necesito-Reyes MJ, Colman H, Dhall G, Lieberman FS, Metellus P, Mikkelsen T, Omuro A, Partap S, Prados M, Robins HI, Soffiotti R, Wu J, Gilbert MR, Armstrong TS, on behalf of the CERN Foundation. Clinical course and progression-free survival of adult intracranial and spinal ependymoma patients. *Neuro Oncol*. 2014 Aug. **Coauthor or Collaborator**.
21. Jalali S, Singh S, Agnihotri S, Wataya T, Salehi F, Burrell K, Navab R, Croul S, **Aldape K**, Zadeh G. A role for matrix remodeling proteins in invasive and malignant meningiomas. *Neuropathol Appl Neurobiol*. 2014 Jul. **Co-Principal Author**.
22. Tsimberidou AM, Wen S, Hong DS, Wheler JJ, Falchook GS, Fu S, Piha-Paul S, Naing A, Janku F, **Aldape K**, Ye Y, Kurzrock R, Berry D. Personalized Medicine for Patients with Advanced Cancer in the Phase I Program at MD Anderson: Validation and Landmark Analyses. *Clin Cancer Res*. 2014 Jul;15;20(18):4827-36. **Coauthor or Collaborator**.
23. Olar A, Wani KM, Sulman EP, Mansouri A, Zadeh G, Wilson CD, DeMonte F, Fuller GN, **Aldape KD**. Mitotic Index is an Independent Predictor of Recurrence-Free Survival in Meningioma. *Brain Pathol*. 2014 Jul. **Senior Responsible Author**.
24. Zheng Y, Yang W, **Aldape K**, He J, Lu Z. Epidermal growth factor (EGF)-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. *J Biol Chem*. 2014 Jul;289(27):18667. **Coauthor or Collaborator**.
25. Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. *Neuro Oncol*. 2014 Jul. **Coauthor or Collaborator**.

26. Said R, Ye Y, Hong DS, Janku F, Fu S, Naing A, Wheler JJ, Kurzrock R, Thomas C, Palmer GA, Hess KR, **Aldape K**, Tsimberidou AM. Characteristics and survival of patients with advanced cancer and p53 mutations. *Oncotarget*. 2014 Jun;5(11):3871-9. **Coauthor or Collaborator**.
27. Mandel JJ, Olar A, **Aldape KD** and Tremont-Lukats IW. Lambrolizumab induced central nervous system (CNS) toxicity. *J Neurol Sci*. 2014 Jun. 2014 Jun 20. pii: S0022-510X(14)00393-1. doi: 10.1016/j.jns.2014.06.023. **Coauthor or Collaborator**.
28. Gabrusiewicz K, Liu D, Cortes-Santiago N, Hossain MB, Conrad CA, **Aldape KD**, Fuller GN, Marini FC, Alonso MM, Idoate MA, Gilbert MR, Fueyo J, Gomez-Manzano C. Anti-vascular endothelial growth factor therapy-induced glioma invasion is associated with accumulation of Tie2-expressing monocytes. *Oncotarget*. 2014 Apr;5(8):2208-20. **Coauthor or Collaborator**.
29. Portier BP, Kanagal-Shamanna R, Luthra R, Singh R, Routbort MJ, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, **Aldape K**, Patel KP. Quantitative assessment of mutant allele burden in solid tumors by semiconductor-based next-generation sequencing. *Am J Clin Pathol*. 2014 Apr;141(4):559-72.
30. Guan X, Vengoechea J, Zheng S, Sloan AE, Chen Y, Brat DJ, O'Neill BP, de Groot J, Yust-Katz S, Yung WK, Cohen ML, **Aldape KD**, Rosenfeld S, Verhaak RG, Barnholtz-Sloan JS. Molecular subtypes of glioblastoma are relevant to lower grade glioma. *PLoS One*. 2014 Mar;9(3):e91216. e-Pub 3/2014.
31. McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, **Aldape KD**, Steeg PS, Ramaswamy S, Sgroi DC. A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity. *Breast Cancer Res*. 2014 Mar;16(2):R25. e-Pub 3/2014.
32. Vartanian A, Singh SK, Agnihotri S, Jalali S, Burrell K, **Aldape KD**, Zadeh G. GBM's multifaceted landscape: highlighting regional and microenvironmental heterogeneity. *Neuro Oncol*. 2014 Mar. e-Pub.
33. Gilbert MR, Dignam JJ, Armstrong TS, Wefel JS, Blumenthal DT, Vogelbaum MA, Colman H, Chakravarti A, Pugh S, Won M, Jeraj R, Brown PD, Jaeckle KA, Schiff D, Stieber VW, Brachman DG, Werner-Wasik M, Tremont-Lukats IW, Sulman EP, **Aldape KD**, Curran WJ, Mehta MP. A randomized trial of bevacizumab for newly diagnosed glioblastoma. *N Engl J Med*. 2014 Feb;370(8):699-708.
34. The Cancer Genome Atlas Research Network including **Aldape K**. Comprehensive molecular characterization of urothelial bladder carcinoma. *Nature*. 2014 Feb.
35. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, **Aldape KD**, Prados MD, Ligon KL. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. *Neuro Oncol*. 2014 Jan. e-Pub 1/2014.
36. Sturm D, Bender S, Jones DT, Lichter P, Grill J, Becher O, Hawkins C, Majewski J, Jones C, Costello JF, Iavarone A, **Aldape K**, Brennan CW, Jabado N, Pfister SM. Paediatric and adult glioblastoma: multiform (epi)genomic culprits emerge. *Nat Rev Cancer*. 2014 Jan;14(2):92-107.
37. Huse JT, Wallace M, **Aldape KD**, Berger MS, Bettgowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffiatti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) Low-grade Glioma Research Workshop. *Neuro Oncol*. 2013 Dec. e-Pub 12/2013.
38. Beiko J, Suki D, Hess KR, Fox BD, Cheung V, Cabral M, Shonka N, Gilbert MR, Sawaya R, Prabhu SS, Weinberg J, Lang FF, **Aldape KD**, Sulman EP, Rao G, McCutcheon IE, Cahill DP. IDH1 mutant malignant astrocytomas are more amenable to surgical resection and have a survival benefit associated with maximal surgical resection. *Neuro Oncol*. 2013 Dec. e-Pub 12/2013.
39. Jiang Y, Li X, Yang W, Hawke DH, Zheng Y, Xia Y, **Aldape K**, Wei C, Guo F, Chen Y, Lu Z. PKM2 Regulates Chromosome Segregation and Mitosis Progression of Tumor Cells. *Mol Cell*. 2013 Dec. e-Pub 12/2013.

40. Terashima K, Yu A, Chow WY, Hsu WC, Chen P, Wong S, Hung YS, Suzuki T, Nishikawa R, Matsutani M, Nakamura H, Ng HK, Allen JC, **Aldape KD**, Su JM, Adesina AM, Leung HC, Man TK, Lau CC. Genome-wide analysis of DNA copy number alterations and loss of heterozygosity in intracranial germ cell tumors. *Pediatr Blood Cancer*. 2013 Nov. e-Pub 11/2013.
41. Huse JT, **Aldape KD**. The molecular landscape of diffuse glioma and prospects for biomarker development. *Expert Opin Med Diagn*. 2013 Nov;7(6):573-87. e-Pub 10/2013.
42. Gilbert MR, Wang M, **Aldape KD**, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ, Mehta MP. Dose dense temozolomide for newly diagnosed glioblastoma: A randomized phase III clinical trial. *J Clin Oncol*. 2013 Oct. e-Pub 10/2013.
43. Brennan CW, Verhaak RG, McKenna A, Campos B, Nounshmehr H, Salama SR, Zheng S, Chakravarty D, Sanborn JZ, Berman SH, Beroukhi R, Bernard B, Wu CJ, Genovese G, Shmulevich I, Barnholtz-Sloan J, Zou L, Vegesna R, Shukla SA, Ciriello G, Yung WK, Zhang W, Sougnez C, Mikkelsen T, **Aldape K**, Bigner DD, Van Meir EG, Prados M, Sloan A, Black KL, Eschbacher J, Finocchiaro G, Friedman W, Andrews DW, Guha A, Iacocca M, O'Neill BP, Foltz G, Myers J, Weisenberger DJ, Penny R, Kucherlapati R, Perou CM, Hayes DN, Gibbs R, Marra M, Mills GB, Lander E, Spellman P, Wilson R, Sander C, Weinstein J, Meyerson M, Gabriel S, Laird PW, Haussler D, Getz G, Chin L, TCGA Research Network. The somatic genomic landscape of glioblastoma. *Cell*. 2013 Oct;155(22):462-77.
44. Zheng Y, Yang W, **Aldape K**, He J, Lu Z. EGF-enhanced vascular cell adhesion molecule-1 (VCAM-1) expression promotes macrophage and glioblastoma cell interaction and tumor cell invasion. *J Biol Chem*. 2013 Sep. e-Pub 9/2013.
45. Bhat KP, Balasubramanian V, Vaillant B, Ezhilarasan R, Hummelink K, Hollingsworth F, Wani K, Heathcock L, James JD, Goodman LD, Conroy S, Long L, Lelic N, Wang S, Gumin J, Raj D, Kodama Y, Raghunathan A, Olar A, Joshi K, Pelloski CE, Heimberger A, Kim SH, Cahill DP, Rao G, Den Dunnen WF, Boddeke HW, Phillips HS, Nakano I, Lang FF, Colman H, Sulman EP, **Aldape K**. Mesenchymal differentiation mediated by NFkB promotes radiation resistance in glioblastoma. *Cancer Cell*. 2013 Sep;24(3):331-46. e-Pub 8/2013.
46. The Cancer Genome Atlas Research Network including **Aldape K**. The Cancer Genome Atlas Pan-Cancer analysis project. *Nat Genet*. 2013 Sep;45(10):1113-20.
47. Doucette T, Rao G, Rao A, Shen L, **Aldape K**, Wei J, Dziurzynski K, Gilbert M, Heimberger AB. Immune Heterogeneity of Glioblastoma Subtypes: Extrapolation from the Cancer Genome Atlas. *Cancer Immunol Res*. 2013 Aug;1(112).
48. Kanagal-Shamanna R, Portier BP, Singh RR, Routbort MJ, **Aldape KD**, Handal BA, Rahimi H, Reddy NG, Barkoh BA, Mishra BM, Paladugu AV, Manekia JH, Kalhor N, Chowdhuri SR, Staerke GA, Medeiros LJ, Luthra R, Patel KP. Next-generation sequencing-based multi-gene mutation profiling of solid tumors using fine needle aspiration samples: promises and challenges for routine clinical diagnostics. *Mod Pathol*. 2013 Aug. e-Pub 8/2013.
49. Zhang S, Huang WC, Zhang L, Zhang C, Lowery FJ, Ding Z, Guo H, Wang H, Huang S, Sahin AA, **Aldape KD**, Steeg PS, Yu D. Src family kinases as novel therapeutic targets to treat breast cancer brain metastases. *Cancer Res*. 2013 Aug. e-Pub 8/2013.
50. Frattini V, Trifonov V, Chan JM, Castano A, Lia M, Abate F, Keir ST, Ji AX, Zoppoli P, Niola F, Danussi C, Dolgalev I, Porrati P, Pellegatta S, Heguy A, Gupta G, Pisapia DJ, Canoll P, Bruce JN, McLendon RE, Yan H, **Aldape K**, Finocchiaro G, Mikkelsen T, Privé GG, Bigner DD, Lasorella A, Rabadan R, Iavarone A. The integrated landscape of driver genomic alterations in glioblastoma. *Nat Genet*. 2013 Aug. e-Pub 8/2013.
51. Rutledge WC, Kong J, Gao J, Gutman DA, Cooper L, Appin C, Park Y, Scarpace L, Mikkelsen T, Cohen ML, **Aldape KD**, McLendon RE, Lehman NL, Miller CR, Schniederjan MJ, Brennan CW, Moreno CS, Saltz JH, Brat DJ. Tumor-infiltrating lymphocytes in glioblastoma are associated with specific genomic alterations and related to transcriptional class. *Clin Cancer Res*. 2013 Jul. e-Pub 7/2013.
52. Tahmasebi FC, Farmer P, Powell SZ, **Aldape KD**, Fuller GN, Patel S, Hollis P, Chalif D, Eisenberg MB, Li JY. Brain metastases from papillary thyroid carcinomas. *Virchows Arch*. 2013 Apr;462(4):473-80. e-Pub 3/2013.

53. van den Bent MJ, Hartmann C, Preusser M, Ströbel T, Dubbink HJ, Kros JM, von Deimling A, Boisselier B, Sanson M, Halling KC, Diefes KL, **Aldape K**, Giannini C. Interlaboratory comparison of IDH mutation detection. *J Neurooncol*. 2013 Apr;112(2):173-8. e-Pub 1/2013.
54. Greaves WO, Verma S, Patel KP, Davies MA, Barkoh BA, Galbincea JM, Yao H, Lazar AJ, **Aldape KD**, Medeiros LJ, Luthra R. Frequency and Spectrum of BRAF Mutations in a Retrospective, Single-Institution Study of 1112 Cases of Melanoma. *J Mol Diagn*. 2013 Mar;15(2):220-6. e-Pub 12/2012.
55. Raghunathan A, Wani K, Armstrong TS, Vera-Bolanos E, Fouladi M, Gilbertson R, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJ, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robins HI, Soffiatti R, Wu J, Miller CR, Gilbert MR, **Aldape KD**, Collaborative Ependymoma Research Network. Histological predictors of outcome in ependymoma are dependent on anatomic site within the central nervous system. *Brain Pathol*. 2013 Mar. e-Pub 3/2013.
56. Kim YW, Koul D, Kim SH, Lucio-Eterovic AK, Freire PR, Yao J, Wang J, Almeida JS, **Aldape K**, Yung WK. Identification of prognostic gene signatures of glioblastoma: a study based on TCGA data analysis. *Neuro Oncol*. 2013 Mar. e-Pub 3/2013.
57. Reyes SB, Narayanan AS, Lee HS, Tchaicha JH, **Aldape KD**, Lang FF, Tolias KF, McCarty JH. $\alpha\beta$ 8 Integrin Interacts with RhoGDI1 to Regulate Rac1 and Cdc42 Activation and Drive Glioblastoma Cell Invasion. *Mol Biol Cell*. 2013 Feb;24(4):474-82. e-Pub 1/2013.
58. Latha K, Li M, Chumbalkar V, Gururaj A, Hwang Y, Dakeng S, Sawaya R, **Aldape K**, Cavenee WK, Bogler O, Furnari FB. Nuclear EGFRvIII-STAT5b complex contributes to glioblastoma cell survival by direct activation of the Bcl-XL promoter. *Int J Cancer*. 2013 Feb;132(3):509-20. e-Pub 7/2012.
59. Dai B, Gong A, Jing Z, **Aldape KD**, Kang SH, Sawaya R, Huang S. Forkhead Box M1 Is Regulated by Heat Shock Factor 1 and Promotes Glioma Cells Survival under Heat Shock Stress. *J Biol Chem*. 2013 Jan;288(3):1634-42. e-Pub 11/2012.
60. Niola F, Zhao X, Singh D, Sullivan R, Castano A, Verrico A, Zoppoli P, Friedmann-Morvinski D, Sulman E, Barrett L, Zhuang Y, Verma I, Benezra R, **Aldape K**, Iavarone A, Lasorella A. Mesenchymal high-grade glioma is maintained by the ID-RAP1 axis. *J Clin Invest*. 2013 Jan;123(1):405-17. e-Pub 12/2012.
61. Boots-Sprenger SH, Sijben A, Rijntjes J, Tops BB, Idema AJ, Rivera AL, Bleeker FE, Gijtenbeek AM, Diefes K, Heathcock L, **Aldape KD**, Jeuken JW, Wesseling P. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT promoter methylation in gliomas: use with caution. *Mod Pathol*. 2013. e-Pub 2/2013.
62. Zheng S, Fu J, Vegesna R, Mao Y, Heathcock LE, Torres-Garcia W, Ezhilarasan R, Wang S, McKenna A, Chin L, Brennan CW, Yung WK, Weinstein JN, **Aldape KD**, Sulman EP, Chen K, Koul D, Verhaak RG. A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survival. *Genes Dev*. 2013. e-Pub 6/2013.
63. Singh RR, Patel KP, Routbort MJ, Reddy N, Barkoh B, Handal B, Kanagal-Shamanna R, Greaves WO, Medeiros LJ, **Aldape K**, Luthra R. Clinical Validation of a Next-Generation Sequencing Screen for Mutational Hotspots in 46 Cancer-Related Genes. *J Mol Diagn*. 2013. e-Pub 6/2013.
64. The Cancer Genome Atlas Research Network including **Aldape K**. Comprehensive molecular characterization of clear cell renal cell carcinoma. *Nature*. 2013. e-Pub 6/2013.
65. Yang W, Xia Y, Cao Y, Zheng Y, Bu W, Zhang L, You MJ, Koh MY, Cote G, **Aldape K**, Li Y, Verma IM, Chiao PJ, Lu Z. EGFR-Induced and PKC ϵ Monoubiquitylation-Dependent NF- κ B Activation Upregulates PKM2 Expression and Promotes Tumorigenesis. *Mol Cell*. 2012 Dec;48(5):771-84. e-Pub 11/2012.
66. Yang W, Zheng Y, Xia Y, Ji H, Chen X, Guo F, Lyssiotis CA, **Aldape K**, Cantley LC, Lu Z. ERK1/2-dependent phosphorylation and nuclear translocation of PKM2 promotes the Warburg effect. *Nat Cell Biol*. 2012 Dec;14(12):1295-304. e-Pub 11/2012.

67. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, **Aldape K**, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. *Neuro Oncol.* 2012 Dec;14(12):1511-8. e-Pub 10/2012.
68. Sturm D, Witt H, Hovestadt V, Khuong-Quang DA, Jones DT, Konermann C, Pfaff E, Tönjes M, Sill M, Bender S, Kool M, Zapatka M, Becker N, Zucknick M, Hielscher T, Liu XY, Fontebasso AM, Ryzhova M, Albrecht S, Jacob K, Wolter M, Ebinger M, Schuhmann MU, van Meter T, Frühwald MC, Hauch H, Pekrun A, Radlwimmer B, Niehues T, von Komorowski G, Dürken M, Kulozik AE, Madden J, Donson A, Foreman NK, Drissi R, Fouladi M, Scheurlen W, von Deimling A, Monoranu C, Roggendorf W, Herold-Mende C, Unterberg A, Kramm CM, Felsberg J, Hartmann C, Wiestler B, Wick W, Milde T, Witt O, Lindroth AM, Schwartzentruber J, Faury D, Fleming A, Zakrzewska M, Liberski PP, Zakrzewski K, Hauser P, Garami M, Klekner A, Bognar L, Morrissy S, Cavalli F, Taylor MD, van Sluis P, Koster J, Versteeg R, Volckmann R, Mikkelsen T, **Aldape K**, Reifenberger G, Collins VP, Majewski J, Korshunov A, Lichter P, Plass C, Jabado N, Pfister SM. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. *Cancer Cell.* 2012 Oct;22(4):425-37.
69. Yang W, Xia Y, Hawke D, Li X, Liang J, Xing D, **Aldape K**, Hunter T, Alfred Yung WK, Lu Z. PKM2 Phosphorylates Histone H3 and Promotes Gene Transcription and Tumorigenesis. *Cell.* 2012 Aug;150(4):685-96.
70. Olar A, Raghunathan A, Albarracin CT, **Aldape KD**, Cahill DP, Powell SZ, Goodman JC, Fuller GN. Absence of IDH1-R132H mutation predicts rapid progression of nonenhancing diffuse glioma in older adults. *Ann Diagn Pathol.* 2012 Jun;16(3):161-70. e-Pub 12/2011.
71. Panageas KS, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Initial treatment patterns over time for anaplastic oligodendroglial tumors. *Neuro Oncol.* 2012 Jun;14(6):761-7. e-Pub 5/2012.
72. Lassman AB, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. Response to Weltman and Fleury Malheiros, re Lassman et al. *Neuro Oncol.* 2012 Jun;14(6):677-678.
73. Wani K, Armstrong TS, Vera-Bolanos E, Raghunathan A, Ellison D, Gilbertson R, Vaillant B, Goldman S, Packer RJ, Fouladi M, Pollack I, Mikkelsen T, Prados M, Omuro A, Soffiatti R, Ledoux A, Wilson C, Long L, Gilbert MR, **Aldape K**, For the Collaborative Ependymoma Research Network. A prognostic gene expression signature in infratentorial ependymoma. *Acta Neuropathol.* 2012 May;123(5):727-38.
74. Ellezam B, Theeler BJ, Luthra R, Adesina AM, **Aldape KD**, Gilbert MR. Recurrent PIK3CA mutations in rosette-forming glioneuronal tumor. *Acta Neuropathol.* 2012 Feb;123(2):285-7. e-Pub 10/2011.
75. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, **Aldape K**, Hawkins C, Hegi M, Guha A. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. *J Clin Invest.* 2012 Jan;122(1):253-66. e-Pub 12/2011.
76. Sai K, Wang S, Balasubramaniyan V, Conrad C, Lang FF, **Aldape K**, Szymanski S, Fokt I, Dasgupta A, Madden T, Guan S, Chen Z, Alfred Yung WK, Priebe W, Colman H. Induction of cell-cycle arrest and apoptosis in glioblastoma stem-like cells by WP1193, a novel small molecule inhibitor of the JAK2/STAT3 pathway. *J Neurooncol.* 2012. e-Pub 1/2012.
77. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, **Aldape KD**, Cahill DP, Powell SZ, Fuller GN. Isocitrate dehydrogenase 1 R132H mutation is not detected in angiocentric glioma. *Ann Diagn Pathol.* 2012. e-Pub 3/2012.
78. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, **Aldape KD**, Mischel P, Xia J, Dilea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. *Cancer Chemother Pharmacol.* 2012. e-Pub 3/2012.

79. Doucette TA, Kong LY, Yang Y, Ferguson SD, Yang J, Wei J, Qiao W, Fuller GN, Bhat KP, **Aldape K**, Priebe W, Bögler O, Heimberger AB, Rao G. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. *Neuro Oncol.* 2012. e-Pub 6/2012.
80. Ellezam B, Theeler BJ, Walbert T, Mammoser AG, Horbinski C, Kleinschmidt-Demasters BK, Perry A, Puduvalli V, Fuller GN, Bruner JM, **Aldape KD**. Low rate of R132H IDH1 mutation in infratentorial and spinal cord grade II and III diffuse gliomas. *Acta Neuropathol.* 2012. e-Pub 7/2012.
81. Singh D, Chan JM, Zoppoli P, Niola F, Sullivan R, Castano A, Liu EM, Reichel J, Porrati P, Pellegatta S, Qiu K, Gao Z, Ceccarelli M, Riccardi R, Brat DJ, Guha A, **Aldape K**, Golfinos JG, Zagzag D, Mikkelsen T, Finocchiaro G, Lasorella A, Rabadan R, Iavarone A. Transforming Fusions of FGFR and TACC Genes in Human Glioblastoma. *Science.* 2012. e-Pub 7/2012.
82. Amirian ES, Armstrong TS, **Aldape KD**, Gilbert MR, Scheurer ME. Predictors of Survival among Pediatric and Adult Ependymoma Cases: A Study Using Surveillance, Epidemiology, and End Results Data from 1973 to 2007. *Neuroepidemiology.* 2012;39(2):116-124. e-Pub 7/2012.
83. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, **Aldape KD**, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. Evidence for Sequenced Molecular Evolution of IDH1 Mutant Glioblastoma From a Distinct Cell of Origin. *J Clin Oncol.* 2011 Dec;29(34):4482-90. e-Pub 10/2011.
84. Snuderl M, Fazlollahi L, Le LP, Nitta M, Zhelyazkova BH, Davidson CJ, Akhavanfard S, Cahill DP, **Aldape KD**, Betensky RA, Louis DN, Iafrate AJ. Mosaic amplification of multiple receptor tyrosine kinase genes in glioblastoma. *Cancer Cell.* 2011 Dec;20(6):810-7. e-Pub 12/2011.
85. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, **Aldape KD**, Lu Z. Nuclear PKM2 regulates β -catenin transactivation upon EGFR activation. *Nature.* 2011 Dec;480(7375):118-22.
86. Bhat KP, Salazar KL, Balasubramanian V, Wani K, Heathcock L, Hollingsworth F, James JD, Gumin J, Diefes KL, Kim SH, Turski A, Azodi Y, Yang Y, Doucette T, Colman H, Sulman EP, Lang FF, Rao G, Copray S, Vaillant BD, **Aldape KD**. The transcriptional coactivator TAZ regulates mesenchymal differentiation in malignant glioma. *Genes Dev.* 2011 Dec;25(24):2594-609.
87. Febbo PG, Ladanyi M, **Aldape KD**, De Marzo AM, Hammond ME, Hayes DF, Iafrate AJ, Kelley RK, Marcucci G, Ogino S, Pao W, Sgroi DC, Birkeland ML. NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. *J Natl Compr Canc Netw.* 2011 Nov;9(Suppl 5):S1-S32.
88. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, **Aldape KD**, Lamborn KR, Prados MD; North American Brain Tumor Consortium. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? *Neuro Oncol.* 2011 Aug.
89. Molina JR, Agarwal NK, Morales FC, Hayashi Y, **Aldape K**, Cote G, Georgescu MM. PTEN, NHERF1 and PHLPP form a tumor suppressor network that is disabled in glioblastoma. *Oncogene.* 2011 Aug.
90. Chiu WT, Lee HT, Huang FJ, **Aldape KD**, Yao J, Steeg PS, Chou CY, Lu Z, Xie K, Huang S. Caveolin-1 upregulation mediates suppression of primary breast tumor growth and brain metastases by Stat3 inhibition. *Cancer Res.* 2011 Jun. e-Pub 6/2011.
91. Singh MM, Manton CA, Bhat KP, Tsai WW, **Aldape K**, Barton MC, Chandra J. Inhibition of LSD1 sensitizes glioblastoma cells to histone deacetylase inhibitors. *Neuro Oncol.* 2011 Jun. e-Pub 6/2011.
92. Lassman AB, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. *Neuro Oncol.* 2011 Jun;13(6):649-59.

93. Armstrong TS, Prabhu S, **Aldape K**, Hossan B, Kang S, Childress A, Tolentino L, Gilbert MR. A case of soft tissue metastasis from glioblastoma and review of the literature. *J Neurooncol.* 2011 May;103(1):167-72. e-Pub 9/2010.
94. Gu D, Tonthat NK, Lee M, Ji H, Bhat KP, Hollingsworth F, **Aldape KD**, Schumacher MA, Zwaka TP, McCrea PD. Caspase-3 cleavage links delta-catenin to the novel nuclear protein ZIFCAT. *J Biol Chem.* 2011 May. e-Pub 5/2011.
95. Agnihotri S, Wolf A, Munoz DM, Smith CJ, Gajadhar A, Restrepo A, Clarke ID, Fuller GN, Kesari S, Dirks PB, McClade CJ, Stanford WL, **Aldape K**, Mischel PS, Hawkins C, Guha A. A GATA4-regulated tumor suppressor network represses formation of malignant human astrocytomas. *J Exp Med.* 2011 Apr;208(4):689-702. e-Pub 4/2011.
96. Miller CA, Settle SH, Sulman EP, **Aldape KD**, Milosavljevic A. Discovering functional modules by identifying recurrent and mutually exclusive mutational patterns in tumors. *BMC Med Genomics.* 2011 Apr;4(1):34.
97. Cogdell D, Chung W, Liu Y, McDonald JM, **Aldape K**, Issa JP, Fuller GN, Zhang W. Tumor-associated methylation of the putative tumor suppressor AJAP1 gene and association between decreased AJAP1 expression and shorter survival in patients with glioma. *Chin J Cancer.* 2011 Apr;30(4):247-53.
98. de Groot JF, Sulman EP, **Aldape KD**. Multigene sets for clinical application in glioma. *J Natl Compr Canc Netw.* 2011 Apr;9(4):449-57.
99. Sampson JH, **Aldape KD**, Archer GE, Coan A, Desjardins A, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling R, Shi W, Vredenburgh JJ, Bigner DD, Heimberger AB. Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRVIII-expressing tumor cells in patients with glioblastoma. *Neuro Oncol.* 2011 Mar;13(3):324-33. e-Pub 12/2010.
100. Hassaneen W, Levine NB, Suki D, Salaskar AL, de Moura Lima A, McCutcheon IE, Prabhu SS, Lang FF, Demonte F, Rao G, Weinberg JS, Wildrick DM, **Aldape KD**, Sawaya R. Multiple craniotomies in the management of multifocal and multicentric glioblastoma. *J Neurosurg.* 2011 Mar;114(3):576-84. e-Pub 8/2010.
101. Bonato V, Baladandayuthapani V, Broom BM, Sulman EP, **Aldape KD**, Do KA. Bayesian ensemble methods for survival prediction in gene expression data. *Bioinformatics.* 2011 Feb;27(3):359-67. e-Pub 12/2010.
102. Bredel M, Scholtens DM, Yadav AK, Alvarez AA, Renfrow JJ, Chandler JP, Yu IL, Carro MS, Dai F, Tagge MJ, Ferrarese R, Bredel C, Phillips HS, Lukac PJ, Robe PA, Weyerbrock A, Vogel H, Dubner S, Mobley B, He X, Scheck AC, Sikic BI, **Aldape KD**, Chakravarti A, Harsh GR. NFKBIA Deletion in Glioblastomas. *N Engl J Med.* 2011 Feb;364(7):627-37. e-Pub 12/2010.
103. McCarthy BJ, Rankin KM, **Aldape K**, Bondy ML, Brännström T, Broholm H, Feychting M, Il'yasova D, Inskip PD, Johansen C, Melin BS, Ruder AM, Butler MA, Scheurer ME, Schüz J, Schwartzbaum JA, Wrensch MR, Davis FG. Risk factors for oligodendroglial tumors: A pooled international study. *Neuro Oncol.* 2011 Feb;13(2):242-50. e-Pub 12/2010.
104. Staquicini FI, Ozawa MG, Moya CA, Driessen WH, Barbu EM, Nishimori H, Soghomonyan S, Flores LG, Liang X, Paolillo V, Alauddin MM, Basilion JP, Furnari FB, Bogler O, Lang FF, **Aldape KD**, Fuller GN, Höök M, Gelovani JG, Sidman RL, Cavenee WK, Pasqualini R, Arap W. Systemic combinatorial peptide selection yields a non-canonical iron-mimicry mechanism for targeting tumors in a mouse model of human glioblastoma. *J Clin Invest.* 2011 Jan;121(1):161-73. e-Pub 12/2010.
105. Sulman EP, **Aldape K**. The use of global profiling in biomarker development for gliomas. *Brain Pathol.* 2011 Jan;21(1):88-95.
106. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, **Aldape K**, Fuller G, Pudevalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. *Cell Death Dis.* 2011;2(1):e121. e-Pub 2/2011.
107. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, **Aldape K**, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. Phase II Study of Aflibercept in Recurrent Malignant Glioma: A North American Brain Tumor Consortium Study. *J Clin Oncol.* 2011. e-Pub 5/2011.

108. Liu D, Martin V, Fueyo J, Lee OH, Xu J, Cortes-Santiago N, Alonso MM, **Aldape K**, Colman H, Gomez-Manzano C. Tie2/TEK Modulates the Interaction of Glioma and Brain Tumor Stem Cells with Endothelial Cells and Promotes an Invasive Phenotype. *Oncotarget*. 2010 Dec;1(8):700-9.
109. Liu Y, Shete S, Wang LE, El-Zein R, Etzel CJ, Liang FW, Armstrong G, Tsavachidis S, Gilbert MR, **Aldape KD**, Xing J, Wu X, Wei Q, Bondy ML. Gamma-Radiation Sensitivity and Polymorphisms in RAD51L1 Modulate Glioma Risk. *Carcinogenesis*. 2010 Oct;31(10):1762-1769. e-Pub 7/2010.
110. Sampson JH, Heimberger AB, Archer GE, **Aldape KD**, Friedman AH, Friedman HS, Gilbert MR, Herndon JE, McLendon RE, Mitchell DA, Reardon DA, Sawaya R, Schmittling RJ, Shi W, Vredenburgh JJ, Bigner DD. Immunologic Escape After Prolonged Progression-Free Survival With Epidermal Growth Factor Receptor Variant III Peptide Vaccination in Patients With Newly Diagnosed Glioblastoma. *J Clin Oncol*. 2010 Oct;28(31):4722-9. e-Pub 10/2010.
111. Molina JR, Morales FC, Hayashi Y, **Aldape KD**, Georgescu MM. Loss of PTEN binding adapter protein NHERF1 from plasma membrane in glioblastoma contributes to PTEN inactivation. *Cancer Res*. 2010 Sep;70(17):6697-703. e-Pub 8/2010.
112. Lin Q, Balasubramanian K, Fan D, Kim SJ, Guo L, Wang H, Bar-Eli M, **Aldape KD**, Fidler IJ. Reactive astrocytes protect melanoma cells from chemotherapy by sequestering intracellular calcium through gap junction communication channels. *Neoplasia*. 2010 Sep;12(9):748-54.
113. Tchaicha JH, Mobley AK, Hossain MG, **Aldape KD**, McCarty JH. A mosaic mouse model of astrocytoma identifies alpha5beta1 integrin as a negative regulator of tumor angiogenesis. *Oncogene*. 2010 Aug;29(31):4460-4472. e-Pub 6/2010.
114. Armstrong TS, Vera-Bolanos E, Bekele BN, **Aldape K**, Gilbert MR. Adult ependymal tumors: prognosis and the M.D. Anderson Cancer Center experience. *Neuro Oncol*. 2010 Aug;12(8):862-70. e-Pub 2/2010.
115. Wu A, **Aldape K**, Lang FF. High rate of deletion of chromosomes 1p and 19q in insular oligodendroglial tumors. *J Neurooncol*. 2010 Aug;99(1):57-64. e-Pub 12/2009.
116. Fischer I, **Aldape K**. Molecular tools: biology, prognosis, and therapeutic triage. *Neuroimaging Clin N Am*. 2010 Aug;20(3):273-82.
117. McGovern SL, **Aldape KD**, Munsell MF, Mahajan A, DeMonte F, Woo SY. A comparison of World Health Organization tumor grades at recurrence in patients with non-skull base and skull base meningiomas. *J Neurosurg*. 2010 May;112(5):925-33. e-Pub 10/2009.
118. Kilburn L, Okcu MF, Wang T, Cao Y, Renfro-Spelman A, **Aldape KD**, Gilbert MR, Bondy M. Glutathione S-transferase polymorphisms are associated with survival in anaplastic glioma patients. *Cancer*. 2010 May;116(9):2242-9. e-Pub 2/2010.
119. Noushmehr H, Weisenberger DJ, Diefes K, Phillips HS, Pujara K, Berman BP, Pan F, Pelloski CE, Sulman EP, Bhat KP, Verhaak RG, Hoadley KA, Hayes DN, Perou CM, Schmidt HK, Ding L, Wilson RK, Van Den Berg D, Shen H, Bengtsson H, Neuvial P, Cope LM, Buckley J, Herman JG, Baylin SB, Laird PW, **Aldape K**, Cancer Genome Atlas Research Network. Identification of a CpG Island Methylator Phenotype that Defines a Distinct Subgroup of Glioma. *Cancer Cell*. 2010 May;17(5):510-522. e-Pub 4/2010.
120. Liu Y, Shete S, Etzel CJ, Scheurer M, Alexiou G, Armstrong G, Tsavachidis S, Liang FW, Gilbert M, **Aldape K**, Armstrong T, Houlston R, Hosking F, Robertson L, Xiao Y, Wiencke J, Wrensch M, Andersson U, Melin BS, Bondy M. Polymorphisms of LIG4, BTBD2, HMGA2, and RTEL1 genes involved in the double-strand break repair pathway predict glioblastoma survival. *J Clin Oncol*. 2010 May;28(14):2467-74. e-Pub 4/2010.
121. Dai B, Pieper RO, Li D, Wei P, Liu M, Woo SY, **Aldape KD**, Sawaya R, Xie K, Huang S. FoxM1B regulates NEDD4-1 expression, leading to cellular transformation and full malignant phenotype in immortalized human astrocytes. *Cancer Res*. 2010 Apr;70(7):2951-61. e-Pub 3/2010.

122. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, **Aldape KD**. MGMT promoter methylation as an independent prognostic factor in the absence of alkylating chemotherapy in glioblastoma. *Neuro Oncol.* 2010 Feb;12(2):116-21. e-Pub 12/2009.
123. Colman H, Zhang L, Sulman EP, McDonald JM, Shooshtari NL, Rivera A, Popoff S, Nutt CL, Louis DN, Cairncross JG, Gilbert MR, Phillips HS, Mehta MP, Chakravarti A, Pelloski CE, Bhat K, Feuerstein BG, Jenkins RB, **Aldape K**. A multigene predictor of outcome in glioblastoma. *Neuro Oncol.* 2010 Jan;12(1):49-57. e-Pub 10/2009.
124. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, **Aldape KD**, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. *Neuro Oncol.* 2010 Jan;12(1):87-94. e-Pub 12/2009.
125. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, **Aldape KD**, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. *Neuro Oncol.* 2010 Jan;12(1):95-103. e-Pub 12/2009.
126. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, **Aldape K**, Dancey J, Prados MD, Lieberman F, Wen PY. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. *J Neurooncol.* 2010 Jan;96(2):211-217. e-Pub 6/2009.
127. Costa BM, Smith JS, Chen Y, Chen J, Phillips HS, **Aldape KD**, Zardo G, Nigro J, James CD, Fridlyand J, Reis RM, Costello JF. Reversing HOXA9 oncogene activation by PI3K inhibition: epigenetic mechanism and prognostic significance in human glioblastoma. *Cancer Res.* 2010 Jan;70(2):453-62. e-Pub 1/2010.
128. Carro MS, Lim WK, Alvarez MJ, Bollo RJ, Zhao X, Snyder EY, Sulman EP, Anne SL, Doetsch F, Colman H, Lasorella A, **Aldape K**, Califano A, Iavarone A. The transcriptional network for mesenchymal transformation of brain tumours. *Nature.* 2010 Jan;463(7279):318-25. e-Pub 12/2009.
129. Broom BM, Sulman EP, Do KA, Edgerton ME, **Aldape K**. Bagged gene shaving for the robust clustering of high-throughput data. *Int J Bioinform Res Appl.* 2010;6(4):326-43.
130. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, **Aldape KD**, Jain RK, Stiles CD, Egorin MJ, Prados MD. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). *Neuro Oncol.* 2009 Dec;11(6):853-860.
131. Ji H, Wang J, Nika H, Hawke D, Keezer S, Ge Q, Fang B, Fang X, Fang D, Litchfield DW, **Aldape K**, Lu Z. EGF-Induced ERK Activation Promotes CK2-Mediated Disassociation of alpha-Catenin from beta-Catenin and Transactivation of beta-Catenin. *Mol Cell.* 2009 Nov;36(4):547-559.
132. Palmieri D, Fitzgerald D, Shreeve SM, Hua E, Bronder JL, Weil RJ, Davis S, Stark AM, Merino MJ, Kurek R, Mehdorn HM, Davis G, Steinberg SM, Meltzer PS, **Aldape K**, Steeg PS. Analyses of Resected Human Brain Metastases of Breast Cancer Reveal the Association between Up-regulation of Hexokinase 2 and Poor Prognosis. *Mol Cancer Res.* 2009 Sep;7(9):1438-1445. e-Pub 9/2009.
133. Sun M, Behrens C, Feng L, Ozburn N, Tang X, Yin G, Komaki R, Varella-Garcia M, Hong WK, **Aldape KD**, Wistuba II. HER family receptor abnormalities in lung cancer brain metastases and corresponding primary tumors. *Clin Cancer Res.* 2009 Aug;15(15):4829-37. e-Pub 7/2009.
134. Zheng Y, Xia Y, Hawke D, Halle M, Tremblay ML, Gao X, Zhou XZ, **Aldape K**, Cobb MH, Xie K, He J, Lu Z. FAK phosphorylation by ERK primes ras-induced tyrosine dephosphorylation of FAK mediated by PIN1 and PTP-PEST. *Mol Cell.* 2009 Jul;35(1):11-25.
135. Piao Y, Jiang H, Alemany R, Krasnykh V, Marini FC, Xu J, Alonso MM, Conrad CA, **Aldape KD**, Gomez-Manzano C, Fueyo J. Oncolytic adenovirus retargeted to Delta-EGFR induces selective anti-glioma activity. *Cancer Gene Ther.* 2009 Mar;16(3):256-65. e-Pub 10/2008.

136. Liu Y, Scheurer ME, El-Zein R, Cao Y, Do KA, Gilbert M, **Aldape KD**, Wei Q, Etzel C, Bondy ML. Association and interactions between DNA repair gene polymorphisms and adult glioma. *Cancer Epidemiol Biomarkers Prev.* 2009 Jan;18(1):204-14.
137. Davies MA, Stemke-Hale K, Lin E, Tellez C, Deng W, Gopal YN, Woodman SE, Calderone TC, Ju Z, Lazar AJ, Prieto VG, **Aldape K**, Mills GB, Gershenwald JE. Integrated Molecular and Clinical Analysis of AKT Activation in Metastatic Melanoma. *Clin Cancer Res.* 2009;15(24):7538-7546.
138. Yip S, Miao J, Cahill DP, Iafrate AJ, **Aldape K**, Nutt CL, Louis DN. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance. *Clin Cancer Res.* 2009;15(14):4622-9.
139. Zhao X, D' Arca D, Lim WK, Brahmachary M, Carro MS, Ludwig T, Cardo CC, Guillemot F, **Aldape K**, Califano A, Iavarone A, Lasorella A. The N-Myc-DLL3 Cascade Is Suppressed by the Ubiquitin Ligase Huwe1 to Inhibit Proliferation and Promote Neurogenesis in the Developing Brain. *Dev Cell.* 2009;17(2):210-21.
140. Sperduto CM, Chakravarti A, **Aldape KD**, Burger P, Papermaster GB, Sperduto P. Twenty-Year Survival In Glioblastoma: A Case Report And Molecular Profile. *Int J Radiat Oncol Biol Phys.* 2009;75(4):1162-1165.
141. Sulman EP, Guerrero M, **Aldape K**. Beyond Grade: Molecular Pathology of Malignant Gliomas. *Seminars in Radiation Oncology.* 2009;19(3):142-149.
142. Fischer I, de la Cruz C, Rivera AL, **Aldape K**. Utility of chromogenic in situ hybridization (CISH) for detection of EGFR amplification in glioblastoma: comparison with fluorescence in situ hybridization (FISH). *Diagn Mol Pathol.* 2008 Dec;17(4):227-30. e-Pub 2008.
143. Gomez-Manzano C, Holash J, Fueyo J, Xu J, Conrad CA, **Aldape KD**, de Groot JF, Bekele BN, Yung WK. VEGF Trap induces antiglioma effect at different stages of disease. *Neuro Oncol.* 2008 Dec;10(6):940-5. e-Pub 8/2008.
144. Freire P, Vilela M, Deus H, Kim YW, Koul D, Colman H, **Aldape KD**, Bogler O, Yung WK, Coombes K, Mills GB, Vasconcelos AT, Almeida JS. Exploratory analysis of the copy number alterations in glioblastoma multiforme. *PLoS One.* 2008 Dec;3(12):e4076. e-Pub 12/2008.
145. Scheurer ME, Amirian E, Cao Y, Gilbert MR, **Aldape KD**, Kornguth DG, El-Zein R, Bondy ML. Polymorphisms in the interleukin-4 receptor gene are associated with better survival in patients with glioblastoma. *Clin Cancer Res.* 2008 Oct;14(20):6640-6.
146. Bhat KP, Pelloski CE, Zhang Y, Kim SH, deLaCruz C, Rehli M, **Aldape KD**. Selective repression of YKL-40 by NF-kappaB in glioma cell lines involves recruitment of histone deacetylase-1 and -2. *FEBS Lett.* 2008 Sep;582(21-22):3192-200. e-Pub 8/2008.
147. Xie TX, **Aldape KD**, Gong W, Kanzawa T, Suki D, Kondo S, Lang F, Ali-Osman F, Sawaya R, Huang S. Aberrant NF-kappaB activity is critical in focal necrosis formation of human glioblastoma by regulation of the expression of tissue factor. *Int J Oncol.* 2008 Jul;33(0):5-15.
148. Scheurer ME, Bondy ML, **Aldape KD**, Albrecht T, El-Zein R. Detection of human cytomegalovirus in different histological types of gliomas. *Acta Neuropathol.* 2008 Jul;116(1):79-86. e-Pub 3/2008.
149. Scheurer ME, El-Zein R, Thompson PA, **Aldape KD**, Levin VA, Gilbert MR, Weinberg JS, Bondy ML. Long-term anti-inflammatory and antihistamine medication use and adult glioma risk. *Cancer Epidemiol Biomarkers Prev.* 2008 May;17(5):1277-81.
150. Aoki H, Kondo Y, **Aldape K**, Yamamoto A, Iwado E, Yokoyama T, Hollingsworth EF, Kobayashi R, Hess K, Shinojima N, Shingu T, Tamada Y, Zhang L, Conrad C, Bogler O, Mills G, Sawaya R, Kondo S. Monitoring autophagy in glioblastoma with antibody against isoform B of human microtubule-associated protein 1 light chain 3. *Autophagy.* 2008 May;4(4):467-75. e-Pub 2/2008.
151. Diehn M, Nardini C, Wang DS, McGovern S, Jayaraman M, Liang Y, **Aldape K**, Cha S, Kuo MD. Identification of noninvasive imaging surrogates for brain tumor gene-expression modules. *Proc Natl Acad Sci U S A.* 2008 Apr;105(13):5213-5218. e-Pub 3/2008.

152. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, **Aldape KD**, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor Consortium. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. *Neuro Oncol.* 2008 Apr;10(2):162-70. e-Pub 3/2008.
153. Davis FG, Malmer BS, **Aldape K**, Barnholtz-Sloan JS, Bondy ML, Brannstrom T, Bruner, JM, Burger PC, Collins VP, Inskip PD, Kruchko C, McCarthy BJ, McLendon RE, Sadetzki S, Tihan T, Wrensch MR, Buffler PA. Issues of diagnostic review in brain tumor studies: From the brain tumor epidemiology consortium. *Cancer Epidemiol Biomarkers Prev.* 2008 Mar;17(3):484-489.
154. Cheung HC, Baggerly KA, Tsavachidis S, Bachinski LL, Neubauer VL, Nixon TJ, **Aldape KD**, Cote GJ, Krahe R. Global analysis of aberrant pre-mRNA splicing in glioblastoma using exon expression arrays. *BMC Genomics.* 2008;12(9):216.
155. Heimberger AB, Sun W, Hussain SF, Dey M, Crutcher L, **Aldape K**, Gilbert M, Hassenbusch SJ, Sawaya R, Schmittling B, Archer GE, Mitchell DA, Bigner DD, Sampson JH. Immunological responses in a patient with glioblastoma multiforme treated with sequential courses of temozolomide and immunotherapy: Case study. *Neuro Oncol.* 2008;10:98-103.
156. Colman H, **Aldape K**. Molecular predictors in glioblastoma: toward personalized therapy. *Arch Neurol.* 2008;65(7):877-883.
157. de Groot JF, Gilbert MR, **Aldape K**, Hess KR, Hanna TA, Ictech S, Groves MD, Conrad C, Colman H, Puduvalli VK, Levin V, Yung WK. Phase II study of carboplatin and erlotinib (Tarceva, OSI-774) in patients with recurrent glioblastoma. *J Neurooncol.* 2008;90(1):89-97.
158. Rivera AL, Pelloski CE, Sulman E, **Aldape K**. Prognostic and predictive markers in glioma and other neuroepithelial tumors. *Curr Probl Cancer.* 2008;32(3):97-123.
159. Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, **Aldape K**. Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. *Brain Pathol.* 2008;18(3):360-369.
160. Sulman E, **Aldape K**, Colman H. Brain tumor stem cells. *Curr Probl Cancer.* 2008;32(3):124-42.
161. TCGA Consortium including **Aldape K**, Bogler O and Yung WK. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. *Nature.* 2008;455(7216):1061-8.
162. Dawood S, Broglio K, Esteva FJ, Ibrahim NK, Kau SW, Islam R, **Aldape KD**, Ye TK, Hortobagyi GN, Gonzalez-Angulo AM. Defining prognosis for women with breast cancer and CNS metastases by HER2 status. *Ann Oncol.* 2008;19(7):1242-8.
163. McDonald JM, Pelloski CE, Ledoux A, Sun M, Raso G, Komaki R, Wistuba II, Bekele BN, **Aldape K**. Elevated phospho-S6 expression is associated with metastasis in adenocarcinoma of the lung. *Clin Cancer Res.* 2008;14(23):7832-7.
164. Lohin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Mehta M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, **Aldape KD**, Yung WK. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. *Clin Cancer Res.* 2007 Dec;13(23):7133-8.
165. Scheurer ME, Etzel CJ, Liu M, El-Zein R, Airewele GE, Malmer B, **Aldape KD**, Weinberg JS, Yung WK, Bondy ML. Aggregation of cancer in first-degree relatives of patients with glioma. *Cancer Epidemiol Biomarkers Prev.* 2007 Nov;16(11):2491-2495.
166. Aoki H, Yokoyama T, Fujiwara K, Tari AM, Sawaya R, Suki D, Hess KR, **Aldape KD**, Kondo S, Kumar R, Kondo Y. Phosphorylated Pak1 level in the cytoplasm correlates with shorter survival time in patients with glioblastoma. *Clin Cancer Res.* 2007 Nov;13(22):6603-6609.

167. Levin VA, Jochev JL, Shantz LM, **Aldape KD**. Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy. *Int J Cancer*. 2007 Nov;121(10):2279-2283.
168. Pelloski CE, Ballman KV, Furth AF, Zhang L, Lin E, Sulman EP, Bhat K, McDonald JM, Yung WK, Colman H, Woo SY, Heimberger AB, Suki D, Prados MD, Chang SM, Barker FG, Buckner JC, James CD, **Aldape K**. EGFRvIII status defines distinct subtypes of glioblastoma. *J Clin Oncol*. 2007 Jun;25(16):2288-2294.
169. Hong C, Moorefield KS, Jun P, **Aldape KD**, Kharbanda S, Phillips HS, Costello JF. Epigenome scans and cancer genome sequencing converge on WNK2, a kinase-independent suppressor of cell growth. *Proc Natl Acad Sci U S A*. 2007 Jun;104(26):10974-10979. e-Pub 6/2007.
170. Palmieri D, Bronder JL, Herring JM, Yoneda T, Weil RJ, Stark AM, Kurek R, Vega-Valle E, Feigenbaum L, Halverson D, Vortmeyer AO, Steinberg SM, **Aldape K**, Steeg PS. Her-2 overexpression increases the metastatic outgrowth of breast cancer cells in the brain. *Cancer Res*. 2007 May;67(9):4190-4198.
171. Olson MV, Johnson DG, Jiang H, Xu J, Alonso MM, **Aldape KD**, Fuller GN, Bekele BN, Yung WK, Gomez-Manzano C, Fueyo J. Transgenic E2F1 expression in the mouse brain induces a human-like bimodal pattern of tumors. *Cancer Res*. 2007 May;67(9):4005-9.
172. Kunwar S, Prados MD, Chang SM, Berger MS, Lang FF, Piepmeier JM, Sampson JH, Ram Z, Gutin PH, Gibbons RD, **Aldape KD**, Croteau DJ, Sherman JW, Puri RK, Cintredekin Besudotox Intraparenchymal Study Group. Direct Intracerebral Delivery of Cintredekin Besudotox (IL13-PE38QQR) in Recurrent Malignant Glioma: A Report by the Cintredekin Besudotox Intraparenchymal Study Group. *J Clin Oncol*. 2007 Mar;25(7):837-44.
173. Sharma MK, Mansur DB, Reifenberger G, Perry A, Leonard JR, **Aldape KD**, Albin MG, Emmett RJ, Loeser S, Watson MA, Nagarajan R, Gutmann DH. Distinct genetic signatures among pilocytic astrocytomas relate to their brain region origin. *Cancer Res*. 2007 Feb;67(3):890-900.
174. Soroceanu L, Kharbanda S, Chen R, Soriano RH, **Aldape K**, Misra A, Sha J, Forrest WF, Nigro JM, Modrusan Z, Feuerstein BG, Phillips HS. Identification of IGF2 signaling through phosphoinositide-3-kinase regulatory subunit 3 as a growth-promoting axis in glioblastoma. *Proc Natl Acad Sci USA*. 2007 Feb;104(9):3466-3471.
175. Puchades M, Nilsson CL, Emmett MR, **Aldape KD**, Ji Y, Lang FF, Liu TJ, Conrad CA. Proteomic investigation of glioblastoma cell lines treated with wild-type p53 and cytotoxic chemotherapy demonstrates an association between galectin-1 and p53 expression. *J Proteome Res*. 2007 Feb;6(2):869-75.
176. **Aldape K**, Burger PC, Perry A. Clinico-pathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. *Arch Pathol Lab Med*. 2007 Feb;131(2):242-251.
177. Chakravarti A, Tyndall E, Palanichamy K, Mehta M, **Aldape K**, Loeffler J. Impact of molecular profiling on clinical trial design for glioblastoma. *Curr Oncol Rep*. 2007 Jan;9(1):71-79.
178. Dai B, Kang SH, Gong W, Liu M, **Aldape KD**, Sawaya R, Huang S. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. *Oncogene*. 2007;26(42):6212-6219.
179. Lee OH, Xu J, Fueyo J, Fuller GN, **Aldape KD**, Alonso MM, Piao Y, Liu TJ, Lang FF, Bekele BN, Gomez-Manzano C. Expression of the receptor tyrosine kinase Tie2 in neoplastic glial cells is associated with integrin beta1-dependent adhesion to the extracellular matrix. *Mol Cancer Res*. 2006 Dec;4(12):915-26.
180. Groves MD, Puduvalli VK, Conrad CA, Gilbert MR, Yung WK, Jaecle K, Liu V, Hess KR, **Aldape KD**, Levin VA. Phase II trial of temozolomide plus marimastat for recurrent anaplastic gliomas: A relationship among efficacy, joint toxicity and anticonvulsant status. *J Neurooncol*. 2006 Oct;80(1):83-90. e-Pub 4/2006.
181. Schwartzbaum JA, Fisher JL, **Aldape KD**, Wrensch M. Epidemiology and molecular pathology of glioma. *Nat Clin Pract Neurol*. 2006 Sep;2(9):494-503. quiz 1 p following 516.

182. Blehm KN, Spiess PE, Bondaruk JE, Dujka ME, Villares GJ, Zhao YJ, Bogler O, **Aldape KD**, Grossman HB, Adam L, McConkey DJ, Czerniak BA, Dinney CP, Bar-Eli M. Mutations within the kinase domain and truncations of the epidermal growth factor receptor are rare events in bladder cancer: implications for therapy. *Clin Cancer Res*. 2006 Aug;12(15):4671-7.
183. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, **Aldape K**, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgu AJ, Stiles C, Prados MD. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American brain tumor consortium study 99-08. *Clin Cancer Res*. 2006 Aug;12(16):4899-4907.
184. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, **Aldape K**, Wright J, Lamborn KR, Prados MD. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: A North American Brain Tumor Consortium study. *J Clin Oncol*. 2006 Aug;24(22):3651-3656.
185. Chakravarti A, Erkinen MG, Nestler U, Stupp R, Mehta M, **Aldape K**, Gilbert MR, Black PM, Loeffler JS. Temozolomide-mediated radiation enhancement in glioblastoma: A report on underlying mechanisms. *Clin Cancer Res*. 2006 Aug;12(15):4738-4746.
186. Pelloski CE, Lin E, Zhang L, Yung WK, Colman H, Liu JL, Woo SY, Heimberger AB, Suki D, Prados M, Chang S, Barker FG, Fuller GN, **Aldape KD**. Prognostic associations of activated mitogen-activated protein kinase and Akt pathways in glioblastoma. *Clin Cancer Res*. 2006 Jul;12(13):3935-41.
187. Hussain SF, Yang D, Suki D, **Aldape K**, Grimm E, Heimberger AB. The role of human glioma-infiltrating microglia / macrophages in mediating antitumor immune responses. *Neuro Oncol*. 2006 Jul;8(3):261-279. e-Pub 6/2006.
188. Rubenstein JL, Fridlyand J, Shen A, **Aldape K**, Ginzinger D, Batchelor T, Treseler P, Berger M, McDermott M, Prados M, Karch J, Okada C, Hyun W, Parikh S, Haqq C, Shuman M. Gene expression and angiotropism in primary CNS lymphoma. *Blood*. 2006 May;107(9):3716-3723.
189. Jiang R, Mircean C, Shmulevich I, Cogdell D, Jia Y, Tabus I, **Aldape K**, Sawaya R, Bruner JM, Fuller GN, Zhang W. Pathway alterations during glioma progression revealed by reverse phase protein lysate arrays. *Proteomics*. 2006 May;6(10):2964-2971.
190. Lee OH, Fueyo J, Xu J, Yung WK, Lemoine MG, Lang FF, Bekele BN, Zhou X, Alonso MA, **Aldape KD**, Fuller GN, Gomez-Manzano C. Sustained angiopoietin-2 expression disrupts vessel formation and inhibits glioma growth. *Neoplasia*. 2006 May;8(5):419-28.
191. Liu M, Dai B, Kang SH, Ban K, Huang FJ, Lang FF, **Aldape KD**, Xie TX, Pelloski CE, Xie K, Sawaya R, Huang S. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. *Cancer Res*. 2006 Apr;66(7):3593-3602.
192. Liang Y, Bollen AW, **Aldape KD**, Gupta N. Nuclear FABP7 immunoreactivity is preferentially expressed in infiltrative glioma and is associated with poor prognosis in EGFR-overexpressing glioblastoma. *BMC Cancer*. 2006 Apr;6:97.
193. Wrensch M, Wiencke JK, Wiemels J, Miike R, Patoka J, Moghadassi M, McMillan A, Kelsey KT, **Aldape K**, Lamborn KR, Parsa AT, Sison JD, Prados MD. Serum IgE, tumor epidermal growth factor receptor expression, and inherited polymorphisms associated with glioma survival. *Cancer Res*. 2006 Apr;66(8):4531-41.
194. Wang L, Wei Q, Wang LE, **Aldape KD**, Cao Y, Okcu MF, Hess KR, El-Zein R, Gilbert MR, Woo SY, Prabhu SS, Fuller GN, Bondy ML. Survival prediction in patients with glioblastoma multiforme by human telomerase genetic variation. *J Clin Oncol*. 2006 Apr;24(10):1627-1632.
195. Su X, Gopalakrishnan V, Stearns D, **Aldape K**, Lang FF, Fuller G, Snyder E, Eberhart CG, Majumder S. Abnormal expression of REST/NRSF and Myc in neural stem / progenitor cells causes cerebellar tumors by blocking neuronal differentiation. *Mol Cell Biol*. 2006 Mar;26(5):1666-1678.
196. Xie TX, Huang FJ, **Aldape KD**, Kang SH, Liu M, Gershenwald JE, Xie K, Sawaya R, Huang S. Activation of stat3 in human melanoma promotes brain metastasis. *Cancer Res*. 2006 Mar;66(6):3188-3196.

197. Phillips HS, Kharbanda S, Chen R, Forrest WF, Soriano RH, Wu TD, Misra A, Nigro JM, Colman H, Soroceanu L, Williams PM, Modrusan Z, Feuerstein BG, **Aldape K**. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. *Cancer Cell*. 2006 Mar;9(3):157-173.
198. McDonald JM, Dunlap S, Cogdell D, Dunmire V, Wei Q, Starzinski-Powitz A, Sawaya R, Bruner J, Fuller GN, **Aldape K**, Zhang W. The SHREW1 gene, frequently deleted in oligodendrogliomas, functions to inhibit cell adhesion and migration. *Cancer Biol Ther*. 2006 Mar;5(3):300-304. e-Pub 3/2006.
199. Wrensch M, Rice T, Miike R, McMillan A, Lamborn KR, **Aldape K**, Prados MD. Diagnostic, treatment, and demographic factors influencing survival in a population-based study of adult glioma patients in the San Francisco Bay Area. *Neuro Oncol*. 2006 Jan;8(1):12-26.
200. Sharma MK, Watson MA, Lyman M, Perry A, **Aldape KD**, Deak F, Gutmann DH. Matrilin-2 expression distinguishes clinically relevant subsets of pilocytic astrocytoma. *Neurology*. 2006 Jan;66(1):127-130.
201. Colman H, Giannini C, Huang L, Gonzalez J, Hess K, Bruner J, Fuller G, Langford L, Pelloski C, Aaron J, Burger P, **Aldape K**. Assessment and prognostic significance of mitotic index using the mitosis marker phospho-histone H3 in low and intermediate-grade infiltrating astrocytomas. *Am J Surg Pathol*. 2006;30(5):657-64.
202. **Aldape K**, Colman H, James CD. Models of Malignant Glioma. *Drug Discovery Today: Disease Models*. 2006;3(2):191-196.
203. Alonso MM, Fueyo J, Shay JW, **Aldape KD**, Jiang H, Lee OH, Johnson DG, Xu J, Kondo Y, Kanzawa T, Kyo S, Bekele BN, Zhou X, Nigro J, McDonald JM, Yung WK, Gomez-Manzano C. Expression of transcription factor E2F1 and telomerase in glioblastomas: mechanistic linkage and prognostic significance. *J Natl Cancer Inst*. 2005 Nov;97(21):1589-600.
204. Wrensch M, Fisher JL, Schwartzbaum JA, Bondy M, Berger M, **Aldape KD**. The molecular epidemiology of gliomas in adults. *Neurosurg Focus*. 2005 Nov;19(E5).
205. Marsit CJ, Wiencke JK, Nelson HH, Kim DH, Hinds PW, **Aldape K**, Kelsey KT. Alterations of 9p in squamous cell carcinoma and adenocarcinoma of the lung: association with smoking, TP53, and survival. *Cancer Genet Cytogenet*. 2005 Oct;162(2):115-21.
206. Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, Sison JD, **Aldape K**, McMillan A, Wiemels J, Wiencke JK. ERCC1 and ERCC2 polymorphisms and adult glioma. *Neuro Oncol*. 2005 Oct;7(4):495-507.
207. Heimberger AB, Suki D, Yang D, Shi W, **Aldape K**. The natural history of EGFR and EGFRvIII in glioblastoma patients. *J Transl Med*. 2005 Oct;19(3):38.
208. Wiencke JK, **Aldape K**, McMillan A, Wiemels J, Moghadassi M, Miike R, Kelsey KT, Patoka J, Long J, Wrensch M. Molecular features of adult glioma associated with patient race/ethnicity, age, and a polymorphism in O6-methylguanine-DNA-methyltransferase. *Cancer Epidemiol Biomarkers Prev*. 2005 Jul;14(7):1774-83.
209. Marsit CJ, Zheng S, **Aldape K**, Hinds PW, Nelson HH, Wiencke JK, Kelsey KT. PTEN expression in non-small-cell lung cancer: Evaluating its relation to tumor characteristics, allelic loss, and epigenetic alteration. *Hum Pathol*. 2005 Jul;36(7):768-76.
210. Wrensch M, Weinberg A, Wiencke J, Miike R, Sison J, Wiemels J, Barger G, DeLorenze G, **Aldape K**, Kelsey K. History of chickenpox and shingles and prevalence of antibodies to varicella-zoster virus and three other herpesviruses among adults with glioma and controls. *Am J Epidemiol*. 2005 May;161(10):929-38.
211. Pelloski CE, Mahajan A, Maor M, Chang EL, Woo S, Gilbert M, Colman H, Yang H, Ledoux A, Blair H, Passe S, Jenkins RB, **Aldape KD**. YKL-40 expression is associated with poorer response to radiation and shorter overall survival in glioblastoma. *Clin Cancer Res*. 2005 May;11(9):3326-34.
212. Nigro JM, Misra A, Zhang L, Smirnov I, Colman H, Griffin C, Ozburn N, Chen M, Pan E, Koul D, Yung WK, Feuerstein BG, **Aldape KD**. Integrated array-comparative genomic hybridization and expression array profiles identify clinically relevant molecular subtypes of glioblastoma. *Cancer Res*. 2005 Mar;65(5):1678-86.

213. Gong W, Wang L, Yao JC, Ajani JA, Wei D, **Aldape KD**, Xie K, Sawaya R, Huang S. Expression of activated signal transducer and activator of transcription 3 predicts expression of vascular endothelial growth factor in and angiogenic phenotype of human gastric cancer. *Clin Cancer Res*. 2005 Feb;11(4):1386-93.
214. Heimberger AB, Hlatky R, Suki D, Yang D, Weinberg J, Gilbert M, Sawaya R, **Aldape K**. Prognostic effect of epidermal growth factor receptor and EGFRvIII in glioblastoma multiforme patients. *Clin Cancer Res*. 2005 Feb;11(4):1462-6.
215. McDonald JM, Dunmire V, Taylor E, Sawaya R, Bruner J, Fuller GN, **Aldape K**, Zhang W. Attenuated expression of DFFB is a hallmark of oligodendrogliomas with 1p-allelic loss. *Mol Cancer*. 2005;12(4):35.
216. McAllister SD, Chan C, Taft RJ, Luu T, Abood ME, Moore DH, **Aldape K**, Yount G. Cannabinoids selectively inhibit proliferation and induce death of cultured human glioblastoma multiforme cells. *J Neurooncol*. 2005;74(1):31-40.
217. Liang Y, Diehn M, Watson N, Bollen AW, **Aldape KD**, Nicholas MK, Lamborn KR, Berger MS, Botstein D, Brown PO, Israel MA. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. *Proc Natl Acad Sci U S A*. 2005;102(16):5814-9.
218. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, **Aldape K**, Lamborn KR, Kuhn J, Dancey J, Prados MD. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. *Invest New Drugs*. 2005;23(4):357-61.
219. McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, **Aldape K**. The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. *Cancer*. 2005;104(7):1468-77.
220. Yount G, Solfvin J, Moore D, Schlitz M, Reading M, **Aldape K**, Qian Y. In vitro test of external Qigong. *BMC Complement Altern Med*. 2004 Mar;15(4):5.
221. Yount G, Qian Y, Moore D, Basila D, West J, **Aldape K**, Arvold N, Shalev N, Haas-Kogan D. Berberine sensitizes human glioma cells, but not normal glial cells, to ionizing radiation in vitro. *J Exp Ther Oncol*. 2004;4(2):137-43.
222. Pandita A, **Aldape KD**, Zadeh G, Guha A, James CD. Contrasting in vivo and in vitro fates of glioblastoma cell subpopulations with amplified EGFR. *Genes Chromosomes Cancer*. 2004;39(1):29-36.
223. Watanabe Y, Kameoka S, Gopalakrishnan V, **Aldape KD**, Pan ZZ, Lang FF, Majumder S. Conversion of myoblasts to physiologically active neuronal phenotype. *Genes Dev*. 2004;18(8):889-900.
224. Prabhu SS, **Aldape KD**, Bruner JM, Weinberg JS. Cowden disease with Lhermitte-Duclos disease: case report. *Can J Neurol Sci*. 2004;31(4):542-9.
225. Wrensch M, Kelsey KT, Liu M, Miike R, Moghadassi M, **Aldape K**, McMillan A, Wiencke JK. Glutathione-S-transferase variants and adult glioma. *Cancer Epidemiol Biomarkers Prev*. 2004;13(3):461-7.
226. **Aldape KD**, Ballman K, Furth A, Buckner JC, Giannini C, Burger PC, Scheithauer BW, Jenkins RB, James CD. Immunohistochemical detection of EGFRvIII in high malignancy grade astrocytomas and evaluation of prognostic significance. *J Neuropathol Exp Neurol*. 2004;63(7):700-7.
227. Bohinski RJ, Mendel E, **Aldape KD**, Rhines LD. Intramedullary and extramedullary solitary fibrous tumor of the cervical spine. Case report and review of the literature. *J Neurosurg*. 2004;100(4 Suppl):Spine. 358-63.
228. Marsit CJ, Hasegawa M, Hirao T, Kim DH, **Aldape K**, Hinds PW, Wiencke JK, Nelson HH, Kelsey KT. Loss of heterozygosity of chromosome 3p21 is associated with mutant TP53 and better patient survival in non-small-cell lung cancer. *Cancer Res*. 2004;64(23):8702-7.
229. Umezu-Goto M, Tanyi J, Lahad J, Liu S, Yu S, Lapushin R, Hasegawa Y, Lu Y, Trost R, Bevers T, Jonasch E, **Aldape K**, Liu J, James RD, Ferguson CG, Xu Y, Prestwich GD, Mills GB. Lysophosphatidic acid production and action: validated targets in cancer? *J Cell Biochem*. 2004;92(6):1115-40.
230. Wang LE, Bondy ML, Shen H, El-Zein R, **Aldape K**, Cao Y, Pudavalli V, Levin VA, Yung WK, Wei Q. Polymorphisms of DNA repair genes and risk of glioma. *Cancer Res*. 2004;64(16):5560-3.

231. Perry A, **Aldape KD**, George DH, Burger PC. Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. *Cancer*. 2004;101(10):2318-26.
232. Ribalta T, McCutcheon IE, **Aldape KD**, Bruner JM, Fuller GN. The mitosis-specific antibody anti-phosphohistone-H3 (PHH3) facilitates rapid reliable grading of meningiomas according to WHO 2000 criteria. *Am J Surg Pathol*. 2004;28(11):1532-6.
233. Borowsky AD, Munn RJ, Galvez JJ, Cardiff RD, Ward JM, Morse HC, 3rd, Kogan SC, **Aldape KD**, Louis DN, Bosenberg MW. Mouse models of human cancers (part 3). *Comp Med*. 2004;54(3):258-70.
234. **Aldape KD**, Okcu MF, Bondy ML, Wrensch M. Molecular epidemiology of glioblastoma. *Cancer J*. 2003;9(2):99-106.
235. Zhang L, Miles MF, **Aldape KD**. A model of molecular interactions on short oligonucleotide microarrays. *Nat Biotechnol*. 2003;21(7):818-21.
236. Trebst C, Staugaitis SM, Kivisakk P, Mahad D, Cathcart MK, Tucky B, Wei T, Rani MR, Horuk R, **Aldape KD**, Pardo CA, Lucchinetti CF, Lassmann H, Ransohoff RM. CC chemokine receptor 8 in the central nervous system is associated with phagocytic macrophages. *Am J Pathol*. 2003;162(2):427-38.
237. Trebst C, Staugaitis SM, Tucky B, Wei T, Suzuki K, **Aldape KD**, Pardo CA, Troncoso J, Lassmann H, Ransohoff RM. Chemokine receptors on infiltrating leucocytes in inflammatory pathologies of the central nervous system (CNS). *Neuropathol Appl Neurobiol*. 2003;29(6):584-95.
238. Weiss WA, Burns MJ, Hackett C, **Aldape K**, Hill JR, Kuriyama H, Kuriyama N, Milshteyn N, Roberts T, Wendland MF, DePinho R, Israel MA. Genetic determinants of malignancy in a mouse model for oligodendroglioma. *Cancer Res*. 2003;63(7):1589-95.
239. Hirose Y, **Aldape KD**, Chang S, Lamborn K, Berger MS, Feuerstein BG. Grade II astrocytomas are subgrouped by chromosome aberrations. *Cancer Genet Cytogenet*. 2003;142(1):1-7.
240. Lang FF, Bruner JM, Fuller GN, **Aldape K**, Prados MD, Chang S, Berger MS, McDermott MW, Kunwar SM, Junck LR, Chandler W, Zwiebel JA, Kaplan RS, Yung WK. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. *J Clin Oncol*. 2003;21(13):2508-18.
241. Schmidt MH, Berger MS, Lamborn KR, **Aldape K**, McDermott MW, Prados MD, Chang SM. Repeated operations for infiltrative low-grade gliomas without intervening therapy. *J Neurosurg*. 2003;98(6):1165-9.
242. Rubenstein JL, Combs D, Rosenberg J, Levy A, McDermott M, Damon L, Ignoffo R, **Aldape K**, Shen A, Lee D, Grillo-Lopez A, Shuman MA. Rituximab therapy for CNS lymphomas: Targeting the leptomeningeal compartment. *Blood*. 2003;101(2):466-8.
243. Prabhu SS, **Aldape KD**, Gagel RF, Benjamin RS, Trent JC, McCutcheon IE. Sarcomatous change after sellar irradiation in a growth hormone-secreting pituitary adenoma. *Can J Neurol Sci*. 2003;30(4):378-83.
244. Lee HK, Chang EL, Fuller GN, **Aldape KD**, Atkinson GJ, Levy LB, McCutcheon IE, Maor MH. The prognostic value of neurologic function in astrocytic spinal cord glioma. *Neuro Oncol*. 2003;5(3):208-13.
245. Burton EC, Lamborn KR, Forsyth P, Scott J, O'Campo J, Uyehara-Lock J, Prados M, Berger M, Passe S, Uhm J, O'Neill BP, Jenkins RB, **Aldape KD**. Aberrant p53, mdm2, and proliferation differ in glioblastomas from long-term compared with typical survivors. *Clin Cancer Res*. 2002;8(1):180-7.
246. von Koch CS, Gulati M, **Aldape K**, Berger MS. Familial medulloblastoma: case report of one family and review of the literature. *Neurosurgery*. 2002;51(1):227-33. discussion 233.
247. Burton EC, Lamborn KR, Feuerstein BG, Prados M, Scott J, Forsyth P, Passe S, Jenkins RB, **Aldape KD**. Genetic aberrations defined by comparative genomic hybridization distinguish long-term from typical survivors of glioblastoma. *Cancer Res*. 2002;62(21):6205-10.
248. Rubenstein J, Fischbein N, **Aldape K**, Burton E, Shuman M. Hemorrhage and VEGF expression in a case of primary CNS lymphoma. *J Neurooncol*. 2002;58(1):53-6.

249. Katsetos CD, Del VL, Geddes JF, **Aldape K**, Boyd JC, Legido A, Khalili K, Perentes E, Mork SJ. Localization of the neuronal class III beta-tubulin in oligodendrogliomas: comparison with Ki-67 proliferative index and 1p/19q status. *J Neuropathol Exp Neurol*. 2002;61(4):307-20.
250. **Aldape K**, Ginzinger DG, Godfrey TE. Real-time quantitative polymerase chain reaction: a potential tool for genetic analysis in neuropathology. *Brain Pathol*. 2002;12(1):54-66.
251. Sonoda Y, Ozawa T, **Aldape KD**, Deen DF, Berger MS, Pieper RO. Akt pathway activation converts anaplastic astrocytoma to glioblastoma multiforme in a human astrocyte model of glioma. *Cancer Res*. 2001;61(18):6674-8.
252. Simmons ML, Lamborn KR, Takahashi M, Chen P, Israel MA, Berger MS, Godfrey T, Nigro J, Prados M, Chang S, Barker FG 2nd, **Aldape K**. Analysis of complex relationships between age, p53, epidermal growth factor receptor, and survival in glioblastoma patients. *Cancer Res*. 2001;61(3):1122-8.
253. Hirose Y, **Aldape K**, Bollen A, James CD, Brat D, Lamborn K, Berger M, Feuerstein BG. Chromosomal abnormalities subdivide ependymal tumors into clinically relevant groups. *Am J Pathol*. 2001;158(3):1137-43.
254. Nigro JM, Takahashi MA, Ginzinger DG, Law M, Passe S, Jenkins RB, **Aldape K**. Detection of 1p and 19q loss in oligodendroglioma by quantitative microsatellite analysis, a real-time quantitative polymerase chain reaction assay. *Am J Pathol*. 2001;158(4):1253-62.
255. Barker FG 2nd, Simmons ML, Chang SM, Prados MD, Larson DA, Sneed PK, Wara WM, Berger MS, Chen P, Israel MA, **Aldape KD**. EGFR overexpression and radiation response in glioblastoma multiforme. *Int J Radiat Oncol Biol Phys*. 2001;51(2):410-8.
256. Chen P, **Aldape K**, Wiencke JK, Kelsey KT, Miike R, Davis RL, Liu J, Kesler-Diaz A, Takahashi M, Wrensch M. Ethnicity delineates different genetic pathways in malignant glioma. *Cancer Res*. 2001;61(10):3949-54.
257. Sonoda Y, Ozawa T, Hirose Y, **Aldape KD**, McMahon M, Berger MS, Pieper RO. Formation of intracranial tumors by genetically modified human astrocytes defines four pathways critical in the development of human anaplastic astrocytoma. *Cancer Res*. 2001;61(13):4956-60.
258. Soos JM, Krieger JI, Stuve O, King CL, Patarroyo JC, **Aldape K**, Wosik K, Slavin AJ, Nelson PA, Antel JP, Zamvil SS. Malignant glioma cells use MHC class II transactivator (CIITA) promoters III and IV to direct IFN-gamma-inducible CIITA expression and can function as nonprofessional antigen presenting cells in endocytic processing and CD4(+) T-cell activation. *Glia*. 2001;36(3):391-405.
259. Burger PC, Pearl DK, **Aldape K**, Yates AJ, Scheithauer BW, Passe SM, Jenkins RB, James CD. Small cell architecture--a histological equivalent of EGFR amplification in glioblastoma multiforme? *J Neuropathol Exp Neurol*. 2001;60(11):1099-104.
260. Hirose Y, **Aldape K**, Takahashi M, Berger MS, Feuerstein BG. Tissue microdissection and degenerate oligonucleotide primed-polymerase chain reaction (DOP-PCR) is an effective method to analyze genetic aberrations in invasive tumors. *J Mol Diagn*. 2001;3(2):62-7.
261. Chen P, Wiencke J, **Aldape K**, Kesler-Diaz A, Miike R, Kelsey K, Lee M, Liu J, Wrensch M. Association of an ERCC1 polymorphism with adult-onset glioma. *Cancer Epidemiol Biomarkers Prev*. 2000;9(8):843-7.
262. Cooper EC, **Aldape KD**, Abosch A, Barbaro NM, Berger MS, Peacock WS, Jan YN, Jan LY. Colocalization and coassembly of two human brain M-type potassium channel subunits that are mutated in epilepsy. *Proc Natl Acad Sci USA*. 2000;97(9):4914-9.
263. **Aldape K**, Simmons ML, Davis RL, Miike R, Wiencke J, Barger G, Lee M, Chen P, Wrensch M. Discrepancies in diagnoses of neuroepithelial neoplasms: The San Francisco Bay Area Adult Glioma Study. *Cancer*. 2000;88(10):2342-9.
264. Smyth MD, Pitts L, Jackler RK, **Aldape KD**. Metastatic spinal ependymoma presenting as a vestibular schwannoma. Case illustration. *J Neurosurg*. 2000;92(2 Suppl):247.
265. Gualberto A, **Aldape K**, Kozakiewicz K, Tlsty TD. An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control. *Proc Natl Acad Sci U S A*. 1998;95(9):5166-71.

Kenneth D. ALDAPE

266. Ostrowitzki S, Fick J, Roberts TP, Wendland MF, **Aldape KD**, Mann JS, Israel MA, Brasch RC. Comparison of gadopentetate dimeglumine and albumin-(Gd-DTPA)₃₀ for microvessel characterization in an intracranial glioma model. *J Magn Reson Imaging*. 1998;8(4):799-806.
267. Yount GL, Haas-Kogan DA, Levine KS, **Aldape KD**, Israel MA. Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy. *Cancer Res*. 1998;58(17):3819-25.
268. Nigro JM, **Aldape KD**, Hess SM, Tlsty TD. Cellular adhesion regulates p53 protein levels in primary human keratinocytes. *Cancer Res*. 1997;57(17):3635-9.
269. Barker FG, Chen P, Furman F, **Aldape KD**, Edwards MS, Israel MA. P16 deletion and mutation analysis in human brain tumors. *J Neurooncol*. 1997;31(1-2):17-23.
270. Weiss WA, **Aldape K**, Mohapatra G, Feuerstein BG, Bishop JM. Targeted expression of MYCN causes neuroblastoma in transgenic mice. *Embo J*. 1997;16(11):2985-95.
271. Cobbs CS, Levi DS, **Aldape K**, Israel MA. Manganese superoxide dismutase expression in human central nervous system tumors. *Cancer Res*. 1996;56(14):3192-5.
272. Breuss JM, Gallo J, DeLisser HM, Klimanskaya IV, Folkesson HG, Pittet JF, Nishimura SL, **Aldape K**, Landers DV, Carpenter W, et al. Expression of the beta 6 integrin subunit in development, neoplasia and tissue repair suggests a role in epithelial remodeling. *J Cell Sci*. 1995 Jun;108(Pt 6):2241-51.
273. Cobbs CS, Brenman JE, **Aldape KD**, Bredt DS, Israel MA. Expression of nitric oxide synthase in human central nervous system tumors. *Cancer Res*. 1995;55(5):727-30.
274. Brenman JE, Chao DS, Xia H, **Aldape K**, Bredt DS. Nitric oxide synthase complexed with dystrophin and absent from skeletal muscle sarcolemma in Duchenne muscular dystrophy. *Cell*. 1995;82(5):743-52.
275. **Aldape K**, Huizinga H, Bouvier J, McKerrow J. *Naegleria fowleri*: Characterization of a secreted histolytic cysteine protease. *Exp Parasitol*. 1994;78(2):230-41.
276. Herndier, BG, Shiramizu BT, Jewett NE, **Aldape KD**, McGrath MS. Acquired immunodeficiency syndrome-associated T-cell lymphoma: evidence for human immunodeficiency virus type 1-associated T-cell transformation. *Blood*. 1992 Apr;79(7):1768-1774.
277. Cohen FE, Gregoret LM, Amiri P, **Aldape K**, Railey J, McKerrow JH. Arresting tissue invasion of a parasite by protease inhibitors chosen with the aid of computer modeling. *Biochemistry*. 1991;30(47):11221-9.
278. **Aldape KD**, Fox HS, Roberts JP, Ascher NL, Lake JR, Rowley HA. *Cladosporium trichoides* cerebral phaeohyphomycosis in a liver transplant recipient. Report of a case. *Am J Clin Pathol*. 1991;95(4):499-502.
279. Porter AC, Kumamoto C, **Aldape K**, Simoni RD. Role of the b subunit of the *Escherichia coli* proton-translocating ATPase. A mutagenic analysis. *J Biol Chem*. 1985;260(13):8182-7.

2. NON-PEER-REVIEWED PUBLICATIONS

Journal Articles

1. Huse JT, **Aldape KD**. The evolving role of molecular markers in the diagnosis and management of diffuse glioma. *Clin Cancer Res*. 2014 Nov;20(22):5601-11. **Coauthor or Collaborator**.
2. Huse JT, **Aldape K**. CMV and glioma--are we there yet? *Neuro Oncol*. 2014 Nov;16(11). **Coauthor or Collaborator**.
3. Zadeh G, **Aldape K**. RESICstance Is Futile-But Not in Glioblastoma. *Cancer Cell*. 2014 Aug;26(2):156-7. **Senior Responsible Author**.
4. Zadeh G, Bhat KP, **Aldape K**. EGFR and EGFRvIII in Glioblastoma: Partners in Crime. *Cancer Cell*. 2013 Oct;24(4):403-4.

Kenneth D. ALDAPE

5. Olar A, **Aldape KD**. Using the Molecular Classification of Glioblastoma to Inform Personalized Treatment. *J Pathol*. 2013 Oct. e-Pub 10/2013.
6. Bhat KP, **Aldape K**. Not expecting the unexpected: diacylglycerol kinase alpha as a cancer target. *Cancer Discov*. 2013 Jul;3(7):726-7.
7. Olar A, **Aldape KD**. Biomarkers Classification and Therapeutic Decision-Making for Malignant Gliomas. *Curr Treat Options Oncol*. 2012 Dec;13(4):417-36. e-Pub 9/2012.
8. Woodman SE, Lazar AJ, **Aldape KD**, Davies MA. New Strategies in Melanoma: Molecular Testing in Advanced Disease. *Clin Cancer Res*. 2012 Mar;18(5):1195-200. e-Pub 1/2012.
9. Li J, Sulman E, **Aldape K**. Molecular biology of brain tumors. *Handb Clin Neurol*. 2012;104:23-34.
10. Weiss WA, Israel M, Cobbs C, Holland E, James CD, Louis DN, Marks C, McClatchey AI, Roberts T, Van Dyke T, Wetmore C, Chiu IM, Giovannini M, Guha A, Higgins RJ, Marino S, Radovanovic I, Reilly K, **Aldape K**. Neuropathology of genetically engineered mice: Consensus report and recommendations from an international forum. *Oncogene*. 2002;21(49):7453-63.

Case Reports

1. Phelps, R, Collins DE, Kram JA, Stoll P, Wrobel J, Davis R, **Aldape K**, Henton D, Smith CL, Benjamin B, Frank L, Chandler A, Pontiflet E, Giles M, Fannin S, Brashear M, Rosenberg J, Emmons R, Jackson RJ, Rutherford GW. Human Rabies. *MMWR* 43(25):45. 1994.

Abstracts

1. Yip S, Miao J, Cahill DP, Iafrate AJ, **Aldape K**, Nutt CL, Louis DN. MSH6 Mutations Arise in Glioblastomas during Temozolomide Therapy and Mediate Temozolomide Resistance. *Clinical Cancer Research*. 2013 Aug;19(16):4543-4544.
2. Golbourn B, Agnihotri S, Cairns R, Mischel P, **Aldape K**, Hawkins C, Zadeh G, Rutka J. A Retroviral Gene-trap Screen Identifies PTEN Induced KINASE1 (PINK1) as a Negative Regulator of Aerobic Glycolysis in Pediatric and Adult Glioblastoma. *Neuro-Oncology*. 2013 Apr;15:28-28.
3. Mack S, Witt H, Jager N, Zuyderduyn S, Nethery-Brookx K, Garzia L, Zayne K, Wang X, Barszczyk M, Wani K, Bouffet E, Weiss W, Hawkins C, Rutka J, Bader G, **Aldape K**, Dirks P, Pfister S, Korshunov A, Taylor M. Effective Epigenetic Therapy for CIMP plus Posterior Fossa Ependymoma. *Neuro-Oncology*. 2013 Apr;15:22-22.
4. Witt H, Sill M, Mack SC, Wani KM, Lambert S, Tzaridis T, Bender S, Jones DTW, Milde T, Northcott PA, Lichter P, Collins VP, **Aldape K**, Taylor MD, Korshunov A, Pfister SM. Identification of Transcriptomic and Epigenetic Subgroups of Supratentorial Ependymomas. *Neuro-Oncology*. 2013 Apr;15:18-19.
5. Perry AS, Kusne Y, Jabbour M, Mandell E, McDonough W, **Aldape K**, Berens ME, Loftus JC, Rushing EJ, Ghosh S. aPKC-Dependent EGFR and NF-kB Signaling Co-Operate To Promote Glioblastoma Invasion. *Laboratory Investigation*. 2013 Feb;92(1):434A-434A.
6. Shen Q, Ibrahim NK, **Aldape KD**, Sahin A. Breast Cancer with Brain Metastases: Risk Factors and Survival. *Laboratory Investigation*. 2013 Feb;93:69A-69A.
7. Wani K, Deavers M, **Aldape K**, Lazar A, Wang WL. Differential MicroRNA Expression in Low-Grade and High-Grade Cartilaginous Tumors. *Laboratory Investigation*. 2013 Feb;93:23A-23A.
8. Portier BP, Patel KP, Singh R, Routbort M, Handal B, Barkoh BA, Reddy N, Lazar A, Davies M, Medeiros LJ, **Aldape K**, Luthra R. Next Generation Sequencing of a Large Cohort of Solid Tumors Reveals IDH1 Mutations Present in Melanoma at a Higher Frequency Than Expected. *Laboratory Investigation*. 2013 Feb;93:119A-119A.
9. Portier BP, Luthra R, Singh R, Routbort M, Handal B, Reddy N, Barkoh BA, Zuo Z, Medeiros LJ, **Aldape K**, Patel KP. Quantitative Assessment of Mutant Allele Burden in Solid Tumors by Semiconductor Based Multi-Gene Next Generation Sequencing. *Laboratory Investigation*. 2013 Feb;93(499A-500A).

10. Sircar K, Majewski T, Yoo SY, Patel L, Wani K, Tamboli P, Czerniak B, Baggerly K, **Aldape K**. Sarcomatoid and Rhabdoid RCC Show a Similar, Poor Prognosis Molecular Signature That Is Separable from Non-Sarcomatoid RCC. Laboratory Investigation. 2013 Feb;93:249A-249A.
11. Sulman EP, Goodman LD, Wani KM, DeMonte F, **Aldape KD**. A Gene Expression Signature to Predict Meningioma Recurrence. Neuro-Oncology. 2012 Nov;14(6):96-96.
12. Charkravarti A, Wan MH, **Aldape K**, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, Werner-Wasik M, Mehta M. A Revised Recursive Partitioning Analysis Model for Glioblastoma Based Upon Multi-Platform Biomarker Profiles. Neuro-Oncology. 2012 Nov;14(6):56-56.
13. Kanagal-Shamanna R, Singh RR, Routbort MJ, **Aldape KD**, Handal B, Rahimi H, Reddy NG, Barkoh BA, Mishra B, Pladugu AV, Manekia J, Staerkel GA, Medeiros L, Luthra R, Patel KP. Application of Next-Generation Sequencing in Using Fine Needle Aspiration Smears and Cell Blocks from Solid Tumors. Journal of Molecular Diagnostic. 2012 Nov;14(6):705-705.
14. Guan XW, Vengoechea J, Zheng SY, Sloan A, Chen YW, Brat D, O'Neill BP, Cohen M, **Aldape K**, Rosenfeld S, Noushmehr H, Verhaak RG, Barnholtz-Sloan J. Association Between Glioblastoma Molecular Subtypes and Lower-Grade Glioma. Neuro-Oncology. 2012 Nov;14(6):92-92.
15. Vera-Bolanos E, Gilbert MR, **Aldape K**, Necesito-Reyes MJ, Fouladi M, Gajjar A, Goldman S, Metellus P, Mikkelsen T, Omuro A, Packer R, Partap S, Pollack IF, Prados M, Robins HI, Soffietti R, Wu J, Armstrong TS. Clinical Course and Progression-Free Survival of Adult and Pediatric Ependymoma: A Working Model. Neuro-Oncology. 2012 Nov;14(6):77-77.
16. Singh RR, Reddy NG, Barkoh B, Handal B, Patel KP, Routbort M, **Aldape KD**, Medeiros JL, Luthra R. Clinical Validation of a 46 Cancer Gene Mutation Panel using Semi-Conductor Based Next-Generation Sequencing Technology. Journal of Molecular Diagnostic. 2012 Nov;4(6):725-725.
17. Patel KP, Singh R, Reddy N, Routbort M, **Aldape K**, Medeiros L, Sargent R, Chen SS, Yin C, Zuo J, Barkoh BA, Handal B, Paladugu A, Patel R, Rahimi H, Grant F, Luthra R. Comparison of Next Generation Sequencing Platforms for Multi-Gene Mutational Profiling of Hematologic Malignancies in a Clinical Diagnostics Laboratory. Journal of Molecular Diagnostics. 2012 Nov;14(6):660-660.
18. Reddy NG, Singh R, Patel KP, Grant F, Rahimi H, Harmon MA, Handal B, Barkoh BA, Routbort M, **Aldape K**, Medeiros JL, Luthra R. Does Formalin-Fixation and Paraffin-Embedding Affect Genotyping by Next Generation Sequencing. Journal of Molecular Diagnostic. 2012 Nov;14(6):738-738.
19. Raghunathan A, Wani K, Armstrong Ts, Vera-Bolanos E, Fouladi M, Gajjar A, Goldman S, Lehman NL, Metellus P, Mikkelsen T, Necesito-Reyes MJT, Omuro A, Packer RJ, Partap S, Pollack IF, Prados MD, Robbins HI, Soffietti R, Wu J, Gilbert MR, **Aldape KD**. Histological Predictors of Outcome in Ependymoma are Dependent on Tumor Location in the Central Nervous System. Neuro-Oncology. 2012 Nov;14(6):107-108.
20. Cortes-Santiago N, Gabrusiewicz K, Liu D, Hossain MB, Gumin J, Fan XJ, Conrad C, **Aldape K**, Gilbert M, Raghunathan A, Yung WKA, Fueyo J, Gomez-Manzano C. Insight on the Role of Microenvironment in the Recurrence of Malignant Gliomas to Anti-Vascular Endothelial Growth Factor Therapy: Opportunities for New Combined Therapies. Neuro-Oncology. 2012 Nov;14(6):4-4.
21. Cahill DP, Beiko J, Suki D, Prabhu S, Weinberg J, Lang F, Sawaya R, Rao G, McCutcheon I, Barker FG, **Aldape KD**. Multivariate Prediction of IDH1 Mutation Status in Malignant Astrocytomas. Neuro-Oncology. 2012 Nov;14(6):99-99.
22. Chu WT, Lee HT, Huang FJ, **Aldape K**, Yao J, Steeg PS, Lu ZM, Xie KP, Huang SY. Targeted Disruption of STAT3 Signaling Inhibits Tumor Growth and Brain Metastases by Caveolin-1 Upregulation. Neuro-Oncology. 2012 Nov;13(3):14-15.
23. Anderson MD, Raghunathan A, **Aldape KD**, Guller GN, Gilbert MR. Textiloma Resembling Anaplastic Progression of an IDH1 Mutant, Low-Grade Glioma. Neuro-Oncology. 2012 Nov;14(6):67-67.

24. Chakravarti A, Wang M, **Aldape K**, Sulman E, Bredel M, Hegi M, Gilbert M, Curran W, Werner-Wasik M, Mehta M. A Revised RTOG Recursive Partitioning Analysis (RPA) Model for Glioblastoma Based Upon Multiplatform Biomarker Profiles. *International Journal of Radiation Oncology Biology Physics*. 2012 Oct;84(3):S4-S5.
25. Routbort M, Handal B, Patel KP, Singh R, **Aldape, K**, Reddy N, Barkoh B, Riben M, Medeiros J, Luthra R. OncoSeek - A Versatile Annotation and Reporting System for Next Generation Sequencing-Based Clinical Mutation Analysis of Cancer Specimens. *Journal of Molecular Diagnostics*. 2012 Oct;14(6):747-747.
26. Agnihotri S, Gajadhar A, Gorlia T, Margison G, **Aldape K**, Hawkins C, Hegi M, Guha A. Elucidation of DNA Repair Signatures that Confer Resistance to Temozolomide and Poor Survival in Patients. *Neuro-Oncology*. 2012 Sep;14(3):8-8.
27. Olar A, Tran D, Mehta V, Ellezman B, Mohila C, Campbell G, Powell S, Fuller G, **Aldape K**, Adesina A. Deregulation of PI3K/AKT Pathway Is Frequent in Pilocytic Astrocytoma with Anaplastic Features. *Journal of Neuropathology and Experimental Neurology*. 2012 Jun;71(6):578-578.
28. Fueyo J, Gomez-Manzano C, Conrad C, Heimberger A, Vence L, **Aldape K**, Yung WA, Sawaya R, Fuller G, Lang F. Phase I clinical trial in patients with recurrent gliomas: delta-24-RGD oncolytic adenovirus induces an antiglioma immune-response. *Journal of Neurology*. 2012 Jun;259(1):S46-S46.
29. Gilbert MR, Hess KR, Lagrone L, Groves MD, Levin VA, De Groot JF, Loghin Me, Puduvalli VK, Fisch M, Giglio P, Conrad CA, **Aldape KD**, Yung WKA, Anderson MD. Randomized phase II 8-arm factorial study of adjuvant dose-dense (dd) temozolomide (TMZ) with permutations of thalidomide (Thal), isotretinoin (CRA), and/or celecoxib (Cel) for newly diagnosed glioblastoma (GBM). *Journal of Clinical Oncology*. 2012 May;30(15).
30. Vaillant BD, Bhat K, Sulman EP, Balasubramaniyan V, Ezhilarasan R, **Aldape KD**, Colman H. The NF kappa B pathway as a key mediator of the glioblastoma mesenchymal subtype in glioblastoma stem cells and human tumors. *Journal of Clinical Oncology*. 2012 May;30(15).
31. Cahill DP, Beiko J, Cheung V, Suki D, Sawaya R, Prabhu S, Lang F, **Aldape K**, Rao G, McCutcheon I. IDH1 Status Determines the Survival Benefit of Surgical Resection for Malignant Astrocytomas. *Journal of Neurosurgery*. 2012 Apr;117(2):A388-a388.
32. Agnihotri S, Gajadhar AS, Ternamian C, Gorlia T, Diefes KL, Mischel PS, Kelly J, McGown G, Thorncroft M, Carlson BL, Sarkaria JN, Margison GP, **Aldape K**, Hawkins C, Hegi M, Guha A. Alkylpurine-DNA-N-glycosylase confers resistance to temozolomide in xenograft models of glioblastoma multiforme and is associated with poor survival in patients. *Journal of Clinical Investigation*. 2012 Feb;122(2):782-782.
33. Ellezam B, Heathcock L, Fuller GN, Bruner JM, **Aldape KD**. Low Rate of IDH1 R132H Mutation in Adult Non-Supratentorial Low and Intermediate Grade Diffuse Gliomas. *Laboratory Investigation*. 2012 Feb;92(1):430A-430A.
34. Sircar K, Majewski T, Wani K, McDonald J, Baggerly K, Tamboli P, Czerniak B, **Aldape K**. Sarcomatoid Renal Cell Carcinoma Shows a Distinct Transcriptomic Profile That Is Not Associated with Epithelial to Mesenchymal Transition Markers. *Laboratory Investigation*. 2012;92(1):241A-242A.
35. Sulman EP, Cahill DP, Wang MH, Won MH, Hegi ME, Mehta MP, **Aldape KD**, Gilbert MR. A Combined Molecular Clinical Predictor of Survival Validated with the RTOG 0525 Cohort. *Neuro-Oncology*. 2011 Nov;13(3):83-83.
36. Colman, H, Gilbert M, Yung WKA, **Aldape K**, De Groot J, Conrad C, Levin V, Groves M, Loghin M, Chris P. A Phase I Study of Sorafenib with Radiation and Temozolomide in Newly Diagnosed Glioblastoma. *Neuro-Oncology*. 2011 Nov;13(3):61-61.
37. **Aldape KD**, Gilbert M, Cahill D, Wang MH, Won MH, Hegi M, Colman H, Mehta M, Sulman E. Clinical Utility of G-CIMP and IDH1 Status as Dual Prognostic Markers in Glioblastoma. *Neuro-Oncology*. 2011 Nov.
38. Bhat K, Vaillant B, Balasubramaniyan V, Ezhilarasan R, Sulman E, Colman H, **Aldape K**. Contribution of Microglia to Radioresistance and Mesenchymal Differentiation in Glioblastoma. *Neuro-Oncology*. 2011 Nov;13(3):150-151.

39. Cahill D, Wang MH, Won MH, **Aldape K**, Maywald R, Hegi M, Mehta M, Gilbert M, Sulman E, Vogelbaum M. Extent of Resection in Glioblastoma - Variation Between Molecular Risk Groups in RTOG - 0525. *Neuro-Oncology*. 2011 Nov;13(3):160-160.
40. Fu J, Koul D, Wang SZ, Yao J, Gumin JG, Sulman E, Lang F, **Aldape K**, Colman H, Yung AW. Glioblastoma Stem Cell Subtypes Display Different Patterns in Neural Differentiation, Growth, and Invasiveness. *Neuro-Oncology*. 2011 Nov;13(3):149-149.
41. Yang W, Xia Y, Ji H, Zheng Y, Liang J, Huang W, Gao X, **Aldape K**, Lu Z. NCCN Task Force Report: Evaluating the Clinical Utility of Tumor Markers in Oncology. *Nature*. 2011 Nov;9(5):S1-S32.
42. Lassman AB, Wang MH, Gilbert MR, **Aldape KD**, Beumer JJ, Wright J, Takebe N, Puduvalli VK, Hormigo A, Gaur R, Werner-Wasik M, Mehta MP. Phase II Trial of Dasatinib in Target Selected Patients with Recurrent Glioblastoma (RTOG 0627). *Neuro-Oncology*. 2011 Nov;13(3):64-64.
43. Reiner AS, Panageas KS, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldan GB, Wen PY, Ligon KL, Shiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Recursive Partitioning Analysis of Prognostic Variables in Newly Diagnosed Anaplastic Oligodendroglial Tumors. *Neuro-Oncology*. 2011 Nov;13(3):43-44.
44. Gilbert MR, Wanh MH, **Aldape KD**, Stupp R, Hegi M, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan A, Schultz CJ, Erridge SC, Brown PD, Chakravarti A, Curran WJ, Mehta MP. RTOG 0525: A Randomized Phase III Trial Comparing Standard Adjuvant Temozolomide (TMZ) with a Dose-Dense (DD) Schedule in Newly Diagnosed Glioblastoma (GBM). *Neuro-Oncology*. 2011 Nov;13(3):51-51.
45. Chu WT, Lee HT, Huang FJ, **Aldape K**, Yao J, Steeg PS, Lu ZM, Xie KP, Huang SY. Targeted Disruption of STAT3 Signaling Inhibits Tumor Growth and Brain Metastases by CAVEOLIN-1 Upregulation. *Neuro-Oncology*. 2011 Nov;13(33):14-15.
46. Koul D, Fu J, Yao J, Wang SZ, Gumin J, Sulman E, Lang F, **Aldape K**, Colman H, Yung AW. TGF-beta Signaling Pathway Mediates Resistance to PI3K Inhibition in Glioma Stem Cells. *Neuro-Oncology*. 2011 Nov;13(3):149-150.
47. Gopalakrishnan V, Das C, Gireud M, Taylor P, Singh A, Lee D, **Aldape K**, Fuller G, Ji LY, Fangusaro J, Rajaram V, Goldman S, Eberhart C. The Deubiquitylase USP37 Controls P27 Stability in Medulloblastoma. *Neuro-Oncology*. 2011 Nov;13(3):105-105.
48. Panageas KS, Iwamoto FM, Cloughesy TF, **Aldape KD**, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldan GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. Time Trends in Treatment of Anaplastic Oligodendroglial Tumors. *Neuro-Oncology*. 2011 Nov;13(3):62-63.
49. Harsh GR, Scholtens DM, Yadav AK, Chandler JP, Carro MS, Bredel C, Robe PA, **Aldape KD**, Chakravarti A, Bredel M. NFKBIA in Glioblastomas: Tumor Suppressor and Potent Predictor of Outcome. *Journal of Neurosurgery*. 2011 Aug.
50. Salazar K, Vaillant B, Wani K, Hollingsworth F, Diefes K, Doucette T, Gumin J, Patel D, Lang F, Rao G, Bhat K, **Aldape K**, Balasubramaniyan V, Mooij J, Kim S. TAZ as a Regulator of Mesenchymal Transformation and Clinical Aggressiveness in Gliomas. *Journal of Investigative Medicine*. 2011 Apr;59(4):694-695.
51. Raghunathan A, Diefes KL, Heathcock L, Powell SZ, Fuller GN, **Aldape KD**. Concordance Rates of O(6)-Methylguanine DNA-Methyltransferase Promoter Methylation in Primary-Recurrent Paired Glioblastoma Samples. *Laboratory Investigation*. 2011 Feb.
52. Liu Y, Lang F, Xie X, Prabhu S, Xu J, Sampath D, **Aldape K**, Fuller G, Puduvalli VK. Efficacy of adenovirally expressed soluble TRAIL in human glioma organotypic slice culture and glioma xenografts. *Cell Death & Disease*. 2011 Feb;2:e121.

53. Raghunathan A, Olar A, Vogel H, Parker JR, Coventry SC, Debski R, Albarracin CT, **Aldape KD**, Cahill DP, Powell SZ, Fuller GN. Isocitrate Dehydrogenase 1 (IDH1) R132H Mutation Is Not Detected in Angiocentric Glioma. Laboratory Investigation. 2011 Feb;91(1):384A-384A.
54. Kusne Y, Meerson A, Rushing EJ, Yang WW, **Aldape K**, McDonough W, Kislin K, Loftus JC, Berens M, Lu ZM, Ghosh S. Altered APKC signaling contributes to glioblastoma cell migration. Neuro-Oncology. 2010 Dec;12:15.
55. Bhat K, Salazar K, Balasubramaniyan V, Vaillant B, Hollingsworth F, Gumin J, Diefes K, Patel D, Lang F, Colman H, **Aldape K**. A regulatory role for TAZ in proneural to mesenchymal differentiation in glioblastoma. Neuro-Oncology. 2010 Nov;12:23-23.
56. Brennan CW, Brat DJ, **Aldape KD**, Cohen M, Lehman NL, McLendon RE, Miller R, Schniederjan M, Vandenberg SR. Addition of GBM Histological Features and EGFRVIII Expression to the Cancer Genome Atlas: Phenotypic Correlates of Molecular Subclasses. Neuro-Oncology. 2010 Nov;12(4):67-68.
57. Latha K, Chumbalkar V, Li M, Gururaj A, Hwang YH, Maywald R, Dakeng S, Dao LX, Baggerly K, Sawaya R, **Aldape K**, Cavenee W, Furnari F, Bogler O. Analysis of Phosphotyrosine signaling in glioblastoma implicates nuclear EGFR VIII-STAT5B complex in the induction of BCL-XL expression. Neuro-Oncology. 2010 Nov;12:13.
58. Goodman L, Gao F, Gumin J, Ezhilarasan R, Love P, George A, Colman H, Lang F, **Aldape K**, Sulman EP. Identification of CD58 as a novel marker of glioma stem cells which further refines the stem cell marker signature. Neuro-Oncology. 2010 Nov;12:124.
59. Lai A, Kharbanda S, Tran A, Pope W, Solis O, Peale F, Forrest W, Purjara K, Carrillo J, Pandita A, Ellingson B, Bowers C, Soriano R, Mohan S, Yong W, **Aldape K**, Mischel P, Liau L, Nghiemphu P, James CD, Prados M, Westphal M, Lamszus K, Cloughesy T, Phillips H. IDH1 mutant glioblastoma: Evidence for sequenced molecular evolution from a developmentally restricted cell of origin. Neuro-Oncology. 2010 Nov;12:65.
60. Gilbert MR, Wang MH, **Aldape K**, Sorensen AG, Mikkelsen T, Bokstein F, Woo SY, Chmura SJ, Choucair AK, Mehta M. RTOG 0625: A randomized phase II trial of Bevacizumab with either irinotecan (CPT) or dose-dense temozolomide (TMZ) in recurrent glioblastoma (GBM). Neuro-Oncology. 2010 Nov;12:39.
61. Bredel M, Yadav A, Renfrow J, Scholtens D, Bredel C, Chandler J, Tagge M, Lukac P, Robe P, Vogel H, Scheck A, **Aldape K**, Chakravarti A, Harsh GR. NFKBIA Deletion in Glioblastoma Multiforme. J of Neurosurgery. 2010 Jul;113(2):748.
62. Rivera AL, Pelloski CE, Gilbert MR, Colman H, De La Cruz C, Sulman EP, Bekele BN, **Aldape K**. MGMT promoter methylation is predictive of response to radiotherapy and prognostic in the absence of adjuvant alkylating chemotherapy for glioblastoma. Neuro-Oncology. 2010 Jun;12(6):617.
63. Le S, Sanga S, Broom BM, **Aldape K**, Cristini V, Edgerton ME. Analysis of Microarray Data from High Grade Gliomas across Multiple Institutions. Modern Pathology. 2010;23:1897.
64. Brennan CW, Brat DJ, **Aldape K**, Cohen M, Lehman NL, McLendon RE, Miller R, Schniederjan M, Vandenberg SR. Cancer Genome Atlas CNSDW addition of GBM histological features and EGFR VIII expression to the cancer genome atlas: Phenotypic correlates of molecular subclasses. Neuro-Oncology. 2010;12:67-8.
65. Vaillant BD, Bhat K, Balasubramaniyam V, Wang SZ, Gumin J, Sulman E, Lang F, **Aldape K**, Colman H. Glioblastoma stem cells demonstrate distinct gene expression and transcription factor profiles that mirror specific GBM tumor subtypes. Neuro-Oncology. 2010;12:126.
66. Sulman EP, Ezhilarasan R, Goodman LD, Love PN, George A, **Aldape K**. The glioma stem-cell marker podoplanin regulates SRC pathway activation. Neuro-Oncology. 2010;12:126.
67. Terashima K, Hsu J, Chow TW, Nishikawa R, Matsutani M, Nakamura H, Ng HK, **Aldape K**, Su JM, Adekunle A, Allen J, Wong KK, Leung HCE, Man TK, Lau CC. Genomic profiling of intracranial germ cell tumors with single nucleotide polymorphism array. Neuro-Oncology. 2009 Dec;11(6):913.

68. Sulman EP, Eifel PJ, Jhingran A, **Aldape K**, Deavers MT, Klopp AH. Expression is Prognostic for Survival of Patients with Squamous Cell Carcinoma of the Cervix Treated with Definitive Radiation Therapy. *International Journal of Radiation Oncology Biology Physics*. 2009 Nov;75(3):S370-S1.
69. Ezhilarasan R, Love PN, Goodman LD, **Aldape K**, Sulman EP. Expression of c-met in Human Glioblastoma Does Not Correlate with Patient Survival or Clinical Radiation Response. *International Journal of Radiation Oncology Biology Physics*. 2009 Nov;75(3):S252.
70. McGovern SL, **Aldape K**, Munsell MF, Mahajan A, DeMonte F, Woo SY. Non-skull Base Cranial Meningiomas have a Higher Grade at Recurrence than Skull Base Meningiomas. *International Journal of Radiation Oncology Biology Physics*. 2009 Nov;75(3):S241-S2.
71. Gilbert MR, Wang M, **Aldape K**, Lassman A, Sorensen AG, Mikkelsen T, Groves M, Werner-Wasik M, Regine W, Mehta M. RTOG 0625: A phase II study of bevacizumab with irinotecan in recurrent glioblastoma (GBM). *J Clin Onc*. 2009 May;27(15):2011.
72. **Aldape K**, Jones G, Wang M, Hegi M, Janzer RC, Stupp R, Mehta MP, Gilbert MR. MGMT methylation testing in RTOG 0525: A phase III trial of newly diagnosed glioblastoma. *J of Clin Onc*. 2009;27(15):2051.
73. Davies MA, Stemke-Hale K, Calderone T, Deng W, Lazar A, Prieto VG, **Aldape K**, Mills GB, Gershenwald JE. Quantitative assessment of AKT activation in melanoma. *J of Clin Onc*. 2009;27(15):9022.

Book Chapters

1. **Aldape K**, Raghunathan A. Pathology and Molecular Classification. In: *Neuro-oncology The Essentials*. 3rd. New York: Bernstein-Berger; 2015. In Press.
2. Fischer I, Sulman E, **Aldape K**. Molecular Pathogenesis of Glioma: Overview and Therapeutic Implications. In: M Mehta, S Chang, H Newton, A Guha, M Vogelbaum, editor(s). *Principles and Practice of Neuro-Oncology: A Multidisciplinary Approach*. New York: Demos Medical Publishing; 2011. p. 88-99.
3. Sulman EP, Guerrero M, **Aldape K**. Transcription Profiling of Brain Tumors: Tumor Biology and Treatment Stratification. In: EG Van Meir, editor(s). *CNS Cancer: Models, Markers, Prognostic Factors, Targets and Therapeutic Approaches*. 1st. New York: Humana Press; 2009. p. 529-551.
4. **Aldape K**, James CD. Pathology and molecular classification. In: Bernstein M, Berger MS, editor(s). *Neuro-Oncology, The Essentials*. 2nd. New York: Thieme; 2008. p. 18-31.
5. **Aldape K**, Rosenblum M. Astroblastoma. In: *WHO Classification of Tumours of the Central Nervous System*. New York: WHO; 2007. p. 88-89.
6. Kleihues P, Burger PC, **Aldape K**, Brat DJ, Biernat W, Bigner D, Nakazato Y, Plate K, Giangaspero F, von Deimling A, Ohgaki H, Cavenee WK. Glioblastoma. In: *WHO Classification of Tumours of the Central Nervous System*. New York: WHO; 2007. p. 33-49.
7. **Aldape K**, Plate K. Haemangioblastoma. In: *WHO Classification of Tumours of the Central Nervous System*. New York: WHO; 2007. p. 184-186.
8. Fuller GN, **Aldape K**. Neuropathology and molecular biology of intracranial tumors. In: *Tumors of the Brain and Spine*. Springer; 2007. p. 23-35.
9. Tremont-Lukats IW, **Aldape KD**. Astroblastoma. In: *Textbook of Neuro-Oncology*. Philadelphia: Elsevier; 2005. p. 208-211.
10. Yung WKA, Aaron J, **Aldape KD**. Mixed Gliomas. In: *Textbook of Neuro-Oncology*. Philadelphia: Elsevier; 2005. p. 177-189.
11. McDonald JM, Coleman H, Perry A, **Aldape KD**. Molecular and clinical aspects of 1p/19q loss in oligodendroglioma. In: *Genomic and Molecular Neuro-Oncology*. Sudbury (Massachusetts): Jones and Bartlett; 2004. p. 17-30.

Kenneth D. ALDAPE

12. Fuller G, Ribalta T, **Aldape K**, Wong F. Diagnostic techniques. In: Atlas of Cancer. Lippincott Williams & Wilkins Publishers; 2003. p. 542-560.
13. Keles E, **Aldape KD**, Berger MS. Low grade gliomas. In: Youman's Textbook of Neurological Surgery. 5. 2003.
14. Binder DK, Keles GE, **Aldape KD**, Berger MS. Aggressive Glial Neoplasms. In: Textbook of Neurological Surgery. 2. Lippincott Williams & Wilkins Publishers; 2002. p. 1270-1280.
15. Zakhary R, Keles GE, **Aldape KD**, Berger MS. Medulloblastoma and primitive neuroectodermal tumors. In: Brain Tumors. 2nd edition. London: Churchill Livingstone; 2001. p. 605-615.
16. **Aldape KD**, Davis RL. Pathological lesions of the third ventricle and adjacent structures. In: Surgery of the Third Ventricle. Williams and Wilkins; 1997.

E. Patents and Copyrights

A multi-CpG methylation assay to predict outcome in patients with glioblastoma, Patent, Patent pending, Filed, Applied, United States, Aldape, Diefes

Novel MGMT methylation assay in cancer, Patent, Patent Pending, Filed, Applied, United States, Aldape, Diefes

Multigene predictor of outcome in glioblastoma, Patent, Patent pending, Pending, Applied, United States, Aldape, Colman, Zhang

F. Presentations and Special Lectures

1. INTERNATIONAL

Invited Lectures and Presentations

- | | |
|-------------|---|
| 2014 Oct | Keynote Speaker. Molecular pathology of glioma. European Association of Neuro-Oncology biennial meeting. Torino, Italy. |
| 2012 Sep 12 | Biomarkers in malignant glioma. German Neuropathology Society Annual Meeting. Erlangen, Germany. |
| 2012 Jul 6 | Multi-dimensional profiling of diffuse glioma. Seve Ballesteros Foundation Special of Brain Cancer. Barcelona, Spain. |
| 2012 Jun 27 | Prognostic biomarkers in malignant glioma. British Neuro-oncology Society Annual Meeting. Manchester, United Kingdom. |
| 2012 Jun 20 | Prognostic biomarkers in malignant glioma. 19th International Conference on Brain Tumor Biology. Niagara Falls, Canada. |
| 2012 May 22 | Molecular genetics of malignant glioma. International symposium of Brain Tumor Pathology. Nagoya, Japan. |
| 2012 Apr 4 | Prognostic biomarkers in glioma. Indian Society for Neuro-oncology. Bangalore, India. |
| 2012 Mar 21 | Prognostic and predictive markers in malignant glioma. Chinese Society of Neuro-oncology. Guangzhou, China. |
| 2011 Jan | Visiting Professor. Molecular diagnostics of glioma. Labatt Lectureship in Brain Tumors, University of Toronto. Canada. (Lectureship). |
| 2008 Oct | Multigene predictor of outcome in glioblastoma. 5th International Heinrich F. C. Behr-Symposium, DKFZ. Heidelberg, Germany. |

Kenneth D. ALDAPE

- 2008 Aug Modern Neuropathology. First Joint Symposium on Neuro-Oncology / Neurosurgery. San Juan, Puerto Rico.
- 2008 Jun Multigene predictor of outcome in glioblastoma. XIII Congresso Nazionale Associazione Italiana di Neuro-Oncologia. Rome, Italy.
- 2008 Jun Multigene predictor of outcome in newly diagnosed glioblastoma. The 17th International Conference on Brain Tumor Research and Therapy, Saitama Medical University. Hakodate, Japan.
- 2008 Jun Pathology and epidemiology of malignant glioma. Current Trends in the Management of Malignant Gliomas Symposium II. Sapporo, Japan.
- 2008 May Pathology of malignant glioma. Current Trends of Malignant Gliomas II. Rio de Janeiro, Brazil.
- 2008 Mar Multigene predictors of outcome in glioblastoma. Perspectives in Central Nervous System Malignancies IV. Berlin, Germany.
- 2007 Jan Multigene predictor of outcome in glioblastoma. James McDonnell Foundation for Brain Cancer Research. Cordoba, Argentina.
- 2006 May A multigene predictor of outcome in glioblastoma. International Conference on Brain Tumor Research and Therapy, Annual Meeting. Napa, California, United States.
- 2004 Nov YKL-40 and radiation response in glioblastoma. Society for Neuro-Oncology, National Meeting. Canada.
- 2002 Molecular diagnostics of astrocytoma. Society for Neuro-Oncology, National Meeting. Toronto, Ontario, Canada.

Other Presentations, Incl Scientific Exhibitions

- 2010 Sep 18 Molecular Profiling of Glioma to Personalize Therapy. European Association of NeuroOncology. Maastricht, Netherlands. Presenter(s): **Aldape, K.**
- 2006 Oct A multigene predictor of outcome in glioblastoma. American Association of Neuropathologists, Annual Meeting, International Congress of Neuropathology. San Francisco, California, United States.

2. NATIONAL

Invited Lectures and Presentations

- 2011 Oct Genomics of malignant gliomas. Columbia University School of Medicine, Oncology Grand Rounds. New York, New York, United States. (Seminar invitation).
- 2011 Mar Genomics of glioblastoma. Preuss Foundation. San Diego, California, United States. (Seminar invitation).
- 2011 **Visiting Professor.** Molecular Genetics of Glioblastoma. Brian Silber Lecture in Neuro-Oncology, Massachusetts General Hospital. (Lectureship).
- 2010 Jan Molecular Profiling for Samples on Clinical Trial RTOG 05-25. 2009 Semi-Annual RTOG Meeting, RTOG. Tampa, Florida, United States.
- 2009 Feb Multigene predictors of outcome in high grade gliomas. Brain Tumor Program Seminar Series, Memorial Sloan Kettering Cancer Center. New York, New York, United States. (Seminar invitation).
- 2008 Mar Microarray analysis of glioblastoma. Cancer Genome Atlas Project, NCI. Bethesda, Maryland, United States.
- 2007 Oct Multigene predictors of outcome in glioblastoma. 2007 Boston Glioma Research and Therapy. Boston, Massachusetts, United States.
- 2007 Jun The role of molecular profiling in high-grade gliomas. ASCO Education Session. Chicago, Illinois, United States.

Kenneth D. ALDAPE

States.

- 2007 Jun Glioblastoma Oncogenomics. Department of Pathology Grand Rounds, New York University School of Medicine, Pathology. New York, New York, United States. (Seminar invitation).
- 2007 May Molecular profiling of gliomas. Columbia University School of Medicine, Pathology. New York, New York, United States. (Seminar invitation).
- 2007 Apr Glioblastoma oncogenomics: Meet the expert. AACR Annual Meeting. Los Angeles, California, United States.
- 2006 Oct Translational Research in Cancer: Lessons Learned. Harold Amos Minority Medical Faculty Development Program, Robert Wood Johnson Foundation. Dallas, Texas, United States.
- 2006 Oct Molecular subtypes of glioblastoma. American Neurological Association, President's Symposium. Chicago, Illinois, United States.
- 2006 Jun Molecular diagnostics of gliomas. Sister Institution Conference, The University of Texas MD Anderson Cancer Center. Houston, Texas, United States.
- 2006 Predictors of outcome in malignant glioma. Washington University. St. Louis, Missouri, United States. (Seminar invitation).
- 2005 Oct Molecular neuropathology of glioblastoma. Brain Tumor Epidemiology Consortium. Chicago, Illinois, United States.
- 2005 Jun Modeling mouse models of human brain tumors. Washington University. St. Louis, Missouri, United States. (Seminar invitation).
- 2003 Nov Histology, 1p/19q status and survival in anaplastic oligodendroglioma. Society for Neuro-Oncology, National Meeting.
- 2003 May Expression profiling and comparative genomic hybridization identifies novel prognostic genes and genetic regions in glioblastoma. University of California. San Francisco, California, United States. (Seminar invitation).
- 2000 May Molecular genetics of glioblastoma. University of Pittsburgh Department of Pathology. (Seminar invitation).
- 1999 Jun Prognostic markers in glioblastoma. Childrens Hospital Research Institute. Oakland, California, United States. (Seminar invitation).
- 1999 Association of ERCC1 polymorphism with the risk for astrocytic gliomas. Society for Neuro-Oncology Meeting. Chicago, Illinois, United States.
- 1999 Tissue microdissection and DOP-PCR as an effective method to analyze genetic aberrations in low grade astrocytoma. Society for Neuro-Oncology Meeting. Chicago, Illinois, United States.

Other Presentations, Incl Scientific Exhibitions

- 2006 Jan From microarray analysis to multigene predictor: predicting outcome in glioblastoma. Radiation Therapy Oncology Group, Semi-Annual Meeting. Miami, Florida, United States.
- 2005 Jan Molecular correlative studies for glioblastoma clinical trials. Radiation Therapy Oncology Groups, Semi-Annual Meeting. Phoenix, Arizona, United States.
- 2001 Nov Chromosome 19 gain in glioblastoma. Society for Neuro-Oncology, National Meeting. Washington, District of Columbia, United States.
- 2000 Jun Prognostic markers in glioblastoma. American Association of Neuropathologists, National Meeting. San Antonio, Texas, United States.

Kenneth D. ALDAPE

- 2000 Apr Genetic aberrations in long-term survivors of glioblastoma. American Association for Cancer Research.
- 2000 Chromosomal abnormalities in ependymoma depend on location and patient age. AACR Annual Meeting.
- 2000 Detection of chromosome 1p loss in gliomas by quantitative microsatellite analysis. AACR Annual Meeting.
- 2000 Molecular genetic predictors of survival in glioblastoma. AACR Annual Meeting.
- 2000 Targeted expression of v-erbB causes oligodendroglioma in transgenic mice. AACR Annual Meeting.

3. LOCAL

Invited Lectures and Presentations

- 2007 May Genetic and genomic studies of glioblastoma. Department of Cancer Biology's Weekly Seminar Series, The University of Texas MD Anderson Cancer Center. Houston, Texas, United States.
- 2006 Sep Molecular predictors of outcome of glioblastoma. Advances in Oncology Institutional Grand Rounds, The University of Texas MD Anderson Cancer Center. Houston, Texas, United States.

G. Research Supervision

1. PRIMARY OR CO-SUPERVISION

Graduate Education

- 2014 Jun - present **Primary Supervisor.** MSc. Tansy.
- 2008 - present **Primary Supervisor.** PhD. Katrina Salazar, MD.

Postdoctoral Research Fellow (PhD)

- 2010 - present **Primary Supervisor.** Khalida Wani, PhD.
- 2010 - 2012 **Primary Supervisor.** Aditya Raghunathan.
- 2007 - 2009 **Primary Supervisor.** Erik Sulman, MD, PhD.
- 2004 - 2010 **Primary Supervisor.** J. Matthew McDonald, PhD.
- 2004 - 2009 **Primary Supervisor.** Christopher Pelloski, MD.
- 2004 - 2006 **Primary Supervisor.** Krishna Bhat, PhD.

Research Associate

- 2014 Jul - present **Primary Supervisor.** Peter Tonge. Supervisee Position: Scientific Associate III, Supervisee Institution: University of Toronto. *Non-thesis Project.*

2. OTHER SUPERVISION

Graduate Education

Thesis Committee Member

- 2008 - 2010 **G.S.B.S.** Alina N. Raza.
- 2008 - 2010 **G.S.B.S.** Zhiliang Jia.
- 2005 **G.S.B.S.** Diane Medrano.